Citrine Global (CTGL) 10-K 15 Apr 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Mar. 31, 2021	Jun. 30, 2020
Cover [Abstract]
Entity Registrant Name	CITRINE GLOBAL, CORP.
Entity Central Index Key	0001498067
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 113,000,000
Entity Common Stock, Shares Outstanding		942,568,006
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current Assets
Cash and cash equivalents	$ 206,278	$ 17,636
Inventory		34,513
Accounts receivable		9,141
Inventory subject to refund		2,159
Prepaid share based payment to a service provider	1,736,534
Trading securities (Note 8)	521,615
Short-term loan measured at fair value (Note 8)	165,185
Other current assets	19,414	18,522
Total Current assets	2,649,026	81,971
Non-current assets
Right of use asset		14,502
Investments valued under the measurement alternative (Note 3)	450,000
Long-term deposits		4,699
Property and equipment, net	5,502	155,655
Total non-current assets	455,502	174,856
Total assets	3,104,528	256,827
Current Liabilities
Accounts payable and accrued expenses (Note 9 I-J)	476,199	223,841
Related parties		123,494
Fair value of a liability in connection with stock exchange agreement (Note 8)	71,722
Convertible component in convertible notes (Note 5)	381,147
Convertible notes (Note 5)	772,602
Deferred Revenue		4,998
Current maturities of long-term lease liability		7,295
Total current liabilities	1,701,670	359,628
Non-current liability
Lease liability		7,962
Total non-current liability		7,962
Total liabilities	1,701,670	367,590
Redeemable convertible Preferred Stock (Note 6)
Redeemable convertible Series A Preferred Stock, par value $0.0001 per share ("Series A Preferred Stock") 12,413,794 shares authorized; 0 and 10,344,828 issued and outstanding at December 31, 2020 and December 31, 2019, respectively		300,000
Stockholders' Equity (Deficit) (Note 6)
Preferred Stock (excluding redeemable Series A Preferred Stock), par value $0.0001 per share ("Preferred Stock"), 37,586,206 shares authorized at December 31, 2019; none issued and outstanding at December 31, 2019
Common Stock, par value $0.0001 per share ("Common Stock"), 1,500,000,000 and 500,000,000 shares authorized at December 31, 2020 and December 31, 2019, respectively; 942,568,006 and 35,449,400 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively	94,256	3,545
Additional paid-in capital	20,414,217	10,042,496
Stock to be issued	30,000	30,000
Accumulated deficit	(19,241,451)	(10,602,292)
Accumulated other Comprehensive Income	105,836	115,488
Total stockholders' equity (deficit)	1,402,858	(410,763)
Total liabilities and stockholders' equity (deficit)	$ 3,104,528	$ 256,827

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Redeemable Series A Preferred Stock, par value	$ 0.0001	$ 0.0001
Redeemable Series A Preferred Stock, shares authorized	12,413,794	12,413,794
Redeemable Series A Preferred Stock, shares issued	0	10,344,828
Redeemable Series A Preferred Stock, shares outstanding	0	10,344,828
Preferred Stock, par value	$ 0.0001	$ 0.0001
Preferred Stock, shares authorized	37,586,206	37,586,206
Preferred Stock, shares issued
Preferred Stock, shares outstanding
Common Stock, par value	$ 0.0001	$ 0.0001
Common Stock, shares authorized	1,500,000,000	500,000,000
Common Stock, shares issued	942,568,006	35,449,400
Common Stock, shares outstanding	942,568,006	35,449,400

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenues	$ 11,372	$ 149,085
Cost of revenues	(13,621)	(158,514)
Provision for slow moving inventory		(176,183)
Gross loss	(2,249)	(185,612)
Research and development expenses	(17,586)	(114,560)
Marketing, general and administrative expenses	(8,350,073)	(1,535,576)
Gain from deconsolidation of a subsidiary (Note 4)	52,330
Operating loss	(8,317,578)	(1,835,748)
Financing expenses, net:
Fair value adjustment of liability in connection with stock exchange agreement (Note 8)	(71,722)
Change in fair value of trading securities (Note 8)	7,329
Change in fair value of short-term loan measured at fair value (Note 8)	20,185
Change in fair value of convertible component in convertible notes (Note 5)	(287,797)
Other financing expenses, net	10,424	(38,387)
Net loss attributable to Common stockholders	$ (8,639,159)	$ (1,874,135)
Loss per Common Stock (basic and diluted)	$ (0.02)	$ (0.06)
Basic weighted average number of shares of Common Stock outstanding	476,622,892	37,473,278
Comprehensive loss:
Net loss	$ (8,639,159)	$ (1,874,135)
Other comprehensive income (expense) attributable to foreign currency translation	(9,652)	(8,618)
Comprehensive loss	$ (8,648,811)	$ (1,865,517)

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock and Changes in Shareholders' Equity (Deficit) - USD ($)	Redeemable Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Stock to be Issued [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income [Member]	Total
Beginning Balance at Dec. 31, 2018		$ 3,322	$ 9,329,419	$ 30,000	$ (8,728,157)	$ 106,870	$ 741,454
Beginning Balance, shares at Dec. 31, 2018		33,212,036
Issuance of Common Stock and warrants		$ 223	$ 457,232				$ 457,455
Issuance of Common Stock and warrants, shares		2,237,364
Conversion Preferred Stock to Common Stock
Conversion Preferred Stock to Common Stock, shares
Issuance of Common Stock
Issuance of Common Stock, shares
Issuance of Common Stock to Service Provider
Issuance of Common Stock to Service Provider, shares
Waiver of fee by related party			243,377				243,377
Issuance of redeemable Convertible Preferred Stock and related Beneficial Conversion Feature			300,000				300,000
Issuance of redeemable Convertible Preferred Stock and related Beneficial Conversion Feature, shares	10,344,828
Accretion of redeemable Preferred Stock for Beneficial Conversion Feature	$ 300,000		(300,000)				(300,000)
Accretion of redeemable Preferred Stock for Beneficial Conversion Feature, shares
Stock-based compensation			12,468				12,468
Warrants issued in connection with convertible notes (Note 5)
Issuance of Common Stock in exchange investment in marketable securities
Issuance of Common Stock in exchange investment in marketable securities, shares
Other Comprehensive Income (loss)						8,618	$ 8,618
Net loss for the period					(1,874,135)		(1,874,135)
Ending Balance at Dec. 31, 2019	$ 300,000	$ 3,545	10,042,496	30,000	(10,602,292)	115,488	(410,763)
Ending Balance, shares at Dec. 31, 2019	10,344,828	35,449,400
Conversion Preferred Stock to Common Stock	$ (300,000)	$ 1,034	298,966				300,000
Conversion Preferred Stock to Common Stock, shares	(10,344,828)	10,344,828
Issuance of Common Stock		$ 86,500	90,500				177,000
Issuance of Common Stock, shares		864,997,122
Issuance of Common Stock to Service Provider		$ 2,963	9,155,101				9,158,064
Issuance of Common Stock to Service Provider, shares		29,633,186
Waiver of fee by related party			11,417				11,417
Issuance of redeemable Convertible Preferred Stock and related Beneficial Conversion Feature
Issuance of redeemable Convertible Preferred Stock and related Beneficial Conversion Feature, shares
Accretion of redeemable Preferred Stock for Beneficial Conversion Feature
Accretion of redeemable Preferred Stock for Beneficial Conversion Feature, shares
Stock-based compensation
Warrants issued in connection with convertible notes (Note 5)			301,665				301,665
Issuance of Common Stock in exchange investment in marketable securities		$ 214	$ 514,072				$ 514,286
Issuance of Common Stock in exchange investment in marketable securities, shares		2,143,470
Other Comprehensive Income (loss)						$ (9,652)	$ (9,652)
Net loss for the period					(8,639,159)		(8,639,159)
Ending Balance at Dec. 31, 2020		$ 94,256	$ 20,414,217	$ 30,000	$ (19,241,451)	$ 105,836	$ 1,402,858
Ending Balance, shares at Dec. 31, 2020		942,568,006

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (8,639,159)	$ (1,874,135)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	6,992	30,680
Finance expenses, net	2,026
Interest with respect to convertible notes	287,797
Interest and change in fair value of short-term loan measured at fair value	(20,185)
Inventory subject to refund	1,299	44,488
Inventory Impairment		176,183
Change in fair value of trading securities	(7,329)
Gain from deconsolidation of a subsidiary (Note 4)	(52,330)
Share based payment to a service provider	7,421,531
Fair value adjustment of liability in connection with stock exchange agreement (Note 8)	71,722
Management fee waiver by a related party	11,417	243,377
Stock-based compensation		12,468
Changes in operating assets and liabilities:
Note payable		42,866
Accounts receivable	(5,714)	171,938
Net changes in operating leases	(864)
Related parties	(11,372)
Other current assets	(21,928)
Inventory	6,789	56,730
Accounts payable and accrued expenses	258,273	(23,591)
Deferred revenue	(4,998)
Refund liability		(71,837)
Liability for severance pay		(34,744)
Net cash used in operating activities	(696,033)	(1,225,577)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(5,830)	(10,977)
Net cash outflow from deconsolidation of a subsidiary (Appendix A)	(13,810)
Investment valued under the measurement alternative (Note 3)	(450,000)
Short-term loan (Note 8)	(145,000)
Severance pay fund		30,180
Long-term deposit		7,739
Net cash provided by (used in) investing activities	(614,640)	26,942
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from related parties' loans	154,341
Proceeds from issuance of redeemable convertible Preferred Stock		300,000
Proceeds from issuance of Common Stock	177,000	457,455
Proceeds from the issued convertible notes and warrants	1,170,000
Net cash provided by financing activities	1,501,341	757,455
Effect of exchange rates on cash and cash equivalents	(2,026)	(15,899)
Net increase (decrease) in cash and cash equivalents	188,642	(457,079)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	17,636	474,715
CASH AND CASH EQUIVALENTS AT END OF PERIOD	206,278	17,636
Supplemental disclosure of cash flow information:
Cash paid during the year for: Interest
Cash paid during the year for: Taxes
Non-cash transactions:
Conversion Preferred Stock to Common Stock	300,000
Issuance of Common Stock in exchange investment in trade securities	514,286
Appendix A - Net cash outflow from deconsolidation of a subsidiary
Working capital (excluding cash and cash equivalents), net	(217,111)
Long term assets	155,988
Long term liabilities	(5,017)
Gain from deconsolidation of a subsidiary	52,330
Net cash outflow from deconsolidation of a subsidiary	$ (13,810)

General

General	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General	NOTE 1 - GENERAL Citrine Global, Corp. (“Citrine Global” or the “Company”) was incorporated under the laws of the State of Delaware on May 26, 2010. The Company’s Common Stock is traded in the United States on the OTCQB market under the ticker symbol “CTGL.” As reported in the Company’s annual report on Form 10-K for the year ended December 31, 2019, during 2019 the Company’s board of directors (the – “Board”) explored strategic alternatives, which the Company had previously reported might include future acquisitions, a merger with another company, the sale of the Company, or a potential sale of certain assets, including the Company’s then wholly-owned subsidiary Novomic Ltd. (“Novomic”), a technology company engaged in the design, development, and commercialization of unique proprietary and patented delivery platform utilizing vaporization of various natural compounds for multiple health, beauty and wellness applications. As of December 31, 2019, the Company had incurred accumulated losses of approximately $10.6 million, and based on the Company’s projected cash flows, and Company’s cash balance, the Company’s management was of the opinion that without further fundraising, it would not have sufficient resources to enable it to continue advancing its activities, including the development, manufacturing, and marketing of its products, which cast substantial doubt on the entity’s ability to continue as a going concern. On January 6, 2020, the Company’s predecessor company, TechCare Corp., a Delaware corporation (“TechCare”), and Citrine S A L Investment & Holdings Ltd., an Israeli corporation and a major shareholder of the Company (“Citrine S A L”), and a group of related persons and entities (the “Citrine S A L Group”) entered into a Common Stock Purchase Agreement (the “Citrine S A L Group Agreement”), which was later amended and restated on February 23, 2020 (the “AR Citrine S A L Group Agreement”). Pursuant to the AR Citrine Agreement, TechCare agreed to sell Citrine S A L Group and its group of business partners, up to an aggregate of 893,699,276 shares of TechCare’s common stock, representing approximately 95% of TechCare’s fully diluted capital, in two tranches, with the initial tranche of up to 452,063,196 shares of the TechCare’s common stock to be sold conditioned upon (i) the resignation of the Company’s existing members of its board of directors (the “Board”), consisting of Oren Traistman and Yossef De-Levy, (ii) the appointment of each of Ora Elharar Soffer (formerly Ora Meir Soffer), Ilan Ben Ishay and Ilanit Halperin as members of the Board, and (iii) the transfer of the TechCare’s signatory rights to all Company bank accounts in the name of Citrine S A L Group’s nominee. In addition, the AR Citrine S A L Group Agreement provides for the second tranche of up to the remaining number of shares of common stock that will result in Citrine S A L Group, owning 95% of the TechCare’s fully diluted capital stock, to be sold conditioned upon the filing of the Company’s previously approved amendment to its First Amended and Restated Certificate of Incorporation to increase the Company’s authorized capital. On January 6, 2020, definitive agreements were executed for the sale of 90% of the shares in Novomic Ltd. (“Novomic”) to Traistman Radziejewski Fundacja Ltd. (“TRF”), which was completed on May 14, 2020 (the “Novomic Divestment”), and for the issuance and sale of a number of shares equal after the issuance to 95% of the fully diluted capital stock of the Company to Citrine S A L Group, which was amended on February 23, 2020, to provide for the issuance and sale of the shares in stages (the “Citrine Global Transaction”). Shares of the Company were issued and sold in accordance with this amended agreement to Citrine S A L Group on February 27, 2020, March 5, 2020, and, after the Company amended its Certificate of Incorporation to increase its authorized share capital, on November 11, 2020. On February 27, 2020, the resignations of all then serving directors of the Company became effective, and the appointments of Ora Elharar Soffer, Ilan Ben-Ishay, and Ilanit Halperin as new directors became effective. Zviel Gedalihou was appointed as Chief Financial Officer of the Company on March 17, 2020 and was replaced in that role by Ilanit Halperin on May 27, 2020, and Ora Elharar Soffer was appointed Chief Executive Officer of the Company on May 7, 2020. Doron Birger was appointed as a fourth director on September 3, 2020. On July 21, 2020, the Israeli Subsidiary began to work with certain Company shareholders, Beezz Home Technologies Ltd., in which Ora Elharar Soffer, our chairperson and CEO holds shares, and Golden Holdings Neto Ltd., in which Ilan Ben-Ishai, a director of the Company, holds shares, have been working towards establishing an Operational Innovation Center focuses on the medical cannabis industry, CBD, hemp, botanical, food supplements and cosmetics products. Our Board approved the Israeli Subsidiary to proceed with preparations for entering into an agreement to incorporate a new company, named Cannovation Center Israel Ltd., with Beezz Home Technologies Ltd.and Golden Holdings Neto Ltd., and to accept limitations on the Israeli Subsidiary’s rights in the Cannovation Center if and as mandated under Israeli regulations on the involvement of foreign entities. On August 4, 2020, the Board of the Company approved for the Company and its Israeli Subsidiary to proceed with preparations for investing in iBOT Israel Botanicals Ltd., an Israeli botanical nutraceutical company (“iBOT”). iBOT has a manufacturing facility for a wide range of botanical formulations, and part of its strategy is to combine this with hemp and cannabidiol (“CBD”). The Board gave its approval, subject to agreement of definitive terms and receipt of all necessary corporate and other approvals, for a proposed transaction in which (1) the Company would have an option to make one or more investments during a period of 12 months in an aggregate amount of up to $1 million; (2) the investments may be through loans, direct equity purchases, or other means, and would be based on milestones; and (3) iBOT would grant the Company a 25% discount in its next fundraising. In addition, the Board approved for the Company to proceed with preparations for entering a services agreement with iBOT pursuant to which the Company would provide consulting and other services to iBOT. iBOT is controlled by an affiliate of the Company. The Company is still in the process of examining the cooperation and investment in iBOT. As part of this process, the Israeli Subsidiary established a new Israeli subsidiary Cannovation Center Israel Ltd, which was incorporated on August 20, 2020 (the “Cannovation Center Subsidiary”) and the Company’s Israeli Subsidiary holds 60% of the shares in the Cannovation Center Subsidiary. On August 20, 2020, Israeli Subsidiary, Beezz Home Technologies Ltd., and and Golden Holdings Neto Ltd. incorporated Cannovation Center Israel Ltd. Israeli Subsidiary holds 60% of Cannovation Center Israel Ltd.’s shares, while each of Beezz Home Technologies Ltd.and Golden Holdings Neto Ltd. holds 20% of its shares. On November 22, 2020, certain of the Company’s stockholders representing more than 50% of the Company’s outstanding share capital (the “Majority Consenting Stockholders”) approved an amendment to the Company’s Certificate of Incorporation (the “Reverse Stock Split Certificate of Amendment”) in order to effect a reverse stock split of the Company’s common stock pursuant to a range of between 40-to-1 and 100-to-1 (the “Reverse Stock Split”). Pursuant to the Reverse Stock Split, each forty or one hundred shares of common stock, as shall be determined by the Board at a later time, will be automatically converted, without any further action by the stockholders, into one share of common stock. No fractional shares of common stock will be issued as the result of the Reverse Stock Split. Instead, each stockholder of the Company will be entitled to receive one share of common stock in lieu of the fractional share that would have resulted from the Reverse Stock Split. In addition, the Majority Consenting Stockholders also approved the elimination of the Company’s entire authorized class of fifty million (50,000,000) undesignated preferred stock, thereby reducing the total number of shares of capital stock that the Company may issue from one billion five hundred fifty-thousand (1,550,000,000) shares to one billion five hundred thousand (1,500,000,000) shares, all of which are designated as common stock (the “Certificate of Elimination”). The Certificate of Elimination will be effective upon the filing with the Secretary of the State of Delaware, which was not completed as of the date of this annual report’s filing. The Reverse Stock Split Certificate of Amendment will be effective upon receipt of approval from the Financial Industry Regulatory Authority (“FINRA”) and the filing with the Secretary of the State of Delaware, which both were not completed as of the date of the audit of the financial statements. On December 30, 2020, the Ministry of the Economy of the Israeli government approved the grant of 10,000 square meters of industrial land in the Yeruham Biopharma Park to Cannovation Center Israel for building the Cannovation Center, that will include factories, laboratories, logistics and a distribution center for the medical cannabis, CBD, hemp and botanicals industries. Citrine S A L , on behalf of itself and its affiliates and related parties, has furnished the Company with an irrevocable letter of obligation to financially support the Company until June 30, 2022 that will allow it to be operational as planned and budgeted through this period (the “ Irrevocable Letter Based on the Company’s current cash balances, capital raised during the year ended December 31, 2020 and the Irrevocable Letter On March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus (SARS-CoV-2) to be a global pandemic (COVID-19), which continues to spread throughout the world. The COVID-19 pandemic is having significant effects on global markets, supply chains, businesses, and communities. Specifically with respect to the Company, COVID-19 may impact various parts of its 2021 plans, operations and financial results, including but not limited to difficulties in obtaining additional financing. The Company believes it is taking appropriate actions to mitigate the negative impact, including by focusing its activities initially only within the country of Israel. However, the full impact of COVID-19 is unknown and cannot be reasonably estimated as these events are still developing.

Summary of Significant Accounti

Summary of Significant Accounting Policies and Basis of Presentation	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Basis of Presentation	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION The financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Principles of Consolidation The accompanying consolidated financial statements include the accounts of Citrine Global, and its subsidiary, CTGL – Citrine Global Israel Ltd. All significant intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates include fair value estimates of derivative liabilities and assets discussed in Notes 5 and 8, as well as the estimated service period related to share based payment to the Company’s legal advisor (refer to Note 6). Actual results could differ from those estimates. Functional Currency and Foreign Currency Translation and Transactions. Effective May 14, 2020, the Company adopted the U.S. dollar as its functional currency. Prior to May 14, 2020, the functional currency of the Company was the New Israeli Shekel (“NIS”). The change in functional currency of the Company is due to the increased exposure to the U.S. dollar as a result of Sale of the Novomic as described in Note 4 below. Therefore, the currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the U.S. dollar. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Non-monetary assets and liabilities are translated using the historical rate on the date of the transaction. All exchange gains or losses arising from translation of these foreign currency transactions are included in net loss for the year. Cash and cash equivalents Cash equivalents are short-term highly liquid investments which include short term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawals or use that are readily convertible to cash with maturities of three months or less as of the date acquired. Property, plant and equipment, net 1. Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. When an asset is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected in the Statements of Operations and Comprehensive Loss. 2. Rates of depreciation: % Computers and software 33 Electronic equipment 15 Office furniture and equipment 7 – 6 Leasehold improvements 10 Machinery and equipment mainly 20 Trading securities and short-term loan measured at fair value The Company accounts for its investments in trade securities in accordance with Accounting Standards “ASC”) No. 320, “Investments—Debt and Equity Securities.” The Company determines the appropriate classification of its investments in trading securities at the time of purchase and re-evaluates the fair value at each balance sheet date. As of December 31, 2020, all of the Company’s investments in trading securities are classified as held for trade (see also Note 8). Therefore, the Company’s trading securities are recorded at fair value on the balance sheet as well as the short-term loan measured at fair value according to the company’s election. Changes in fair value of trading securities and short-term loan are recorded in financing income (expenses), net in the consolidated statement of operations. Investments valued under the measurement alternative The Company’s investments as described in Notes 3 and 4 are valued under the measurement alternative include equity securities in other proprietary investments for which the Company does not have significant influence and fair value is not readily determinable. Accounting Standard Update (“ASU”) 2016-01 requires equity securities to be recorded at cost and adjusted to fair value at each reporting period. However, the guidance allows for a measurement alternative, which is to record investments at cost, less impairment, if any, and subsequently adjust for observable price changes of identical or similar investments of the same issuer. Due to the lack of readily determinable fair values for such investments, for which the Company does not have significant influence, the Company accounts for these investments under the measurement alternative at cost, less impairment. The Company performs qualitative impairment assessments on its investments recorded under the measurement alternative. Impairment of long-lived assets The Group’s long-lived assets are reviewed for impairment in accordance with ASC Topic 360, “Property, Plant and Equipment”, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Derivatives Derivative instruments are recognized on the balance sheet at their fair value, with changes in the fair value recognized as a component of financial expenses, net in the statements of income. Once determined, derivative liabilities and assets are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. Deferred income taxes The Company accounts for income taxes in accordance with ASC Topic 740, “Income Taxes”. Accordingly, deferred income taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and the tax bases of assets and liabilities under the applicable tax law. Deferred tax balances are computed using the enacted tax rates expected to be in effect when these differences reverse. Valuation allowances in respect of deferred tax assets are provided for, if necessary, to reduce deferred tax assets to amounts more likely than not to be realized. The Company accounts for uncertain tax positions in accordance with ASC Topic 740-10, which prescribes detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in an enterprise’s financial statements. According to ASC Topic 740-10, tax positions must meet a more-likely-than-not recognition threshold. The Company’s accounting policy is to classify interest and penalties relating to uncertain tax positions under income taxes, however the Company did not recognize such items in its fiscal 2020 and 2019 financial statements and did not recognize any liability with respect to an unrecognized tax position in its balance sheets. Revenue recognition Revenues are recognized when delivery has occurred and there is persuasive evidence of an agreement, the fee is fixed or determinable and collection of the related receivables is reasonably assured, and no further obligations exist. Revenues from sales of products are recognized when title and risk and rewards for the products are transferred to the customer. Research and development expenses Research and development costs consist primarily of employee compensation expenses, materials, laboratory supplies, costs s for facilities and equipment. Expenditures for research and development are expensed as incurred. Basic and diluted loss per ordinary share Basic loss per share of Common Stock is computed by dividing the loss for the period applicable to holders of shares of Common Stock, by the weighted average number of shares of Common Stock outstanding during the period. Securities that may participate in dividends with the shares of Common Stock (such as the convertible Preferred Stock) are considered in the computation of basic loss per share under the two-class method. However, in periods of net loss, only the convertible Preferred Stock are considered, since such shares have a contractual obligation to share in the losses of the Company. In computing diluted loss per share, basic loss per share is adjusted to reflect the potential dilution that could occur upon the exercise of potential shares. Accordingly, in periods of net loss, no potential shares are considered. Stock-based compensation The Company measures and recognizes the compensation expense for all equity-based payments based on their estimated fair values in accordance with ASC 718, “Compensation-Stock Compensation”. Share-based payments including grants of stock options are recognized in the statement of comprehensive loss as an operating expense based on the fair value of the award at the date of grant. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model. The Company has expensed compensation costs, net of estimated forfeitures, applying the accelerated vesting method, over the requisite service period or over the implicit service period when a performance condition affects the vesting, and it is considered probable that the performance condition will be achieved. Fair value Fair value of certain of the Company’s financial instruments including cash, accounts receivable, accounts payable, accrued expenses, and other accrued liabilities approximate cost because of their short maturities. The Company measures and reports fair value in accordance with ASC 820, “Fair Value Measurements and Disclosure” defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles and expands disclosures about fair value measurements. Fair value, as defined in ASC 820, is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of an asset should reflect its highest and best use by market participants, principal (or most advantageous) markets, and an in-use or an in-exchange valuation premise. The fair value of a liability should reflect the risk of nonperformance, which includes, among other things, the Company’s credit risk. Valuation techniques are generally classified into three categories: the market approach; the income approach; and the cost approach. The selection and application of one or more of the techniques may require significant judgment and are primarily dependent upon the characteristics of the asset or liability, and the quality and availability of inputs. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 also provides fair value hierarchy for inputs and resulting measurement as follows: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities; and Level 3: Unobservable inputs for the asset or liability that are supported by little or no market activity, and that are significant to the fair values. Fair value measurements are required to be disclosed by the Level within the fair value hierarchy in which the fair value measurements in their entirety fall. Fair value measurements using significant unobservable inputs (in Level 3 measurements) are subject to expanded disclosure requirements including a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (i) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings, and a description of where those gains or losses included in earning are reported in the statement of operations. The Company’s financial assets and liabilities that are measured at fair value on a recurring basis by level within the fair value hierarchy are as follows: Balance as of December 31, 2020 Level 1 Level 2 Level 3 Total Trading securities (Note 8) - 521,615 - 521,615 Short-term loan measured at fair value (Note 8) - - 165,185 165,185 Total assets - 521,615 165,185 686,800 Liabilities: Fair value of convertible component in convertible notes (Note 5) - - 381,147 381,147 Fair Value of forward option (Note 8) - - 71,722 71,722 Total liabilities - - 452,869 452,869 The following table presents the changes in fair value of the level 3 liabilities for the year ended December 31, 2020: Changes in Fair value Assets: Outstanding at January 1, 2020 - Fair value of issued level 3 assets 145,000 Changes in fair value 20,185 Outstanding at December 31, 2020 165,185 Liabilities: Outstanding at January 1, 2020 - Fair value of issued level 3 liability 350,608 Changes in fair value 102,261 Outstanding at December 31, 2020 452,869 Concentrations of credit risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents as well as certain other current assets that do not amount to a significant amount. Cash and cash equivalents, which are primarily held in Dollars and New Israeli Shekels, are deposited with major banks in Israel and United States. Management believes that such financial institutions are financially sound and, accordingly, minimal credit risk exists with respect to these financial instruments. The Company does not have any significant off-balance-sheet concentration of credit risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements. Contingencies The Company records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred. Recent Accounting Pronouncements Accounting Pronouncements Adopted in 2020 In June 2016, the Financial Accounting Standards Board (“FASB”) issued an ASU that supersedes the existing impairment model for most financial assets to a current expected credit loss model. The new guidance requires an entity to recognize an impairment allowance equal to its current estimate of all contractual cash flows the entity does not expect to collect. The Company adopted this guidance effective January 1, 2020, with no material impact on its consolidated financial statements In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. The guidance became effective on January 1, 2020, including interim periods within that year and requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. Under the modified retrospective method of adoption, prior year reported results are not restated. The Company has performed its analysis of the impact on its financial instruments that are within the scope of this guidance and has concluded that there was no material impact to its consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework — Changes to the Disclosure Requirements for Fair Value Measurement” (“ASU No. 2018-13”) as part of the FASB’s broader disclosure framework project. ASU No. 2018-13 removes, modifies and adds certain disclosures, providing greater focus on requirements that clearly communicate the most important information to the users of the financial statements with respect to fair value measurements. The Company’s adoption of ASU No. 2018-13 as of January 1, 2020 did not have a material impact on the Company’s consolidated financial statements. Recently Issued Accounting Pronouncements Not Yet Adopted In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes” (“ASU 2019-12”). The amendments in this ASU simplify the accounting for income taxes, eliminates certain exceptions to the general principles in Topic 740 and clarifies certain aspects of the current guidance to improve consistent application among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021 and interim periods within annual periods beginning after December 15, 2022, though early adoption is permitted, including adoption in any interim period for which financial statements have not yet been issued. This standard is not expected to have a material impact to the Company’s consolidated financial statements after evaluation. In August 2020, the FASB issued ASU No. 2020-06, “Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”. ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible Preferred Stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current U.S. GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective for public companies for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU 2020-06 will have on the Company’s consolidated financial statement presentation or disclosures. Other new pronouncements issued but not effective as of December 31, 2020 are not expected to have a material impact on the Company’s consolidated financial statements.

Investment Valued Under the Mea

Investment Valued Under the Measurement Alternative	12 Months Ended
	Dec. 31, 2020
Investment Valued Under Measurement Alternative
Investment Valued Under the Measurement Alternative	NOTE 3 - INVESTMENT VALUED UNDER THE MEASUREMENT ALTERNATIVE On June 22, 2020, the Company entered into a share purchase agreement with Nanomedic Technologies Ltd., an Israeli private company and a related party as further described below (“Nanomedic”) as part of an A-1 funding round open only to existing Nanomedic shareholders and their affiliates. Nanomedic developed SpinCare™, a system that integrates electrospinning technology into a portable, bedside device, offering immediate wound and burn care treatment. The Company paid $450,000 for A-1 preferred shares of Nanomedic and also received warrants to purchase A-1 preferred shares. Such investment represents a holding of approximately 3.3% in Nanomedic. The round raised approximately $2.2 million in total. Citrine S A L and certain of its partnerships, all affiliates of the Company, were already beneficial shareholders of Nanomedic immediately prior to the A-1 funding round. Ilan Ben-Ishay, a director of the Company was already a beneficial shareholder of Nanomedic immediately prior to the A-1 funding round. Ora Meir Soffer, chairperson and CEO of the Company, was already a director of both Nanomedic and its Israeli parent company Nicast Ltd. immediately prior to the A-1 funding round, and she was also already a beneficial shareholder of Nanomedic immediately prior to the A-1 funding round. The Company accounts for the investment in Nanomedic in accordance with the provisions of ASC 321, “Investments - Equity Securities”, and elected to use the measurement alternative therein. The investment will be re-measured upon future observable price change(s) in orderly transaction(s) or upon impairment, if any.

Sale of Novomic

Sale of Novomic	12 Months Ended
	Dec. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]
Sale of Novomic	NOTE 4 - SALE OF NOVOMIC As described in Note 1 above, on January 6, 2020, definitive agreements were executed for the sale of 90% of the shares in Novomic to TRF, which was completed on May 14, 2020. The remaining investment in Novomic (represents 10% holding) is not presented within the Company’s condensed consolidated balance sheet as of December 31, 2020, as it had no significant value as of that date. Starting on the deconsolidation date, the remaining investment in Novomic is accounted as an investment valued under the measurement alternative as described in Note 2 above. The following table summarizes the assets and liabilities of Novomic as of the deconsolidation date: Cash and cash equivalents 13,810 Working capital (excluding cash and cash equivalents), net (deficit) (217,111 ) Long term assets 155,988 Long term liabilities (5,017 ) (52,330 ) Amounts received - GAIN FROM DECONSOLIDATION OF A SUBSIDIARY $ 52,330

Convertible Notes

Convertible Notes	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Convertible Notes	NOTE 5 – CONVERTIBLE NOTES On April 1, 2020 the Company entered into a Convertible Note Purchase Agreement (the “CL Agreement”) with Citrine S A L , WealthStone Private Equity Ltd, WealthStone Holdings Ltd, Golden Holdings Neto Ltd, Beezz Home Technologies Ltd, Citrine Biotech 5 LP, Citrine High Tech 6 LP, Citrine High Tech 7 LP, Citrine 8 LP, Citrine 9 LP and Citrine Biotech 10 LP (together, the “Buyer”), all of which are affiliated with the Company. Under the CL Agreement, the Buyer agreed to purchase and the Company agreed to issue and sell, for up to an aggregate principal amount of up to $1,800 thousand, notes convertible into shares of Common Stock of the Company (the “Notes”), with a drawdown period starting on April 1, 2020 and ending upon the earlier of (i) 6 months thereafter and (ii) the consummation of a public offering by the Company. The CL Agreement provides that the Notes will bear an annual interest rate of six percent (6%) and that the conversion price per share of Common Stock shall equal 85% multiplied by the market price (as defined in the Notes), representing a discount of 15%, and that each Note will mature 18 months following the payment date. See Note 12A below. On April 19, 2020 and June 12, 2020, the Company provided draw down notices under the CL Agreement for amounts of $170 thousand and $1 million, respectively, which were received in cash by the Company. On June 12, 2020, the CL Agreement was amended (hereafter “Amendment”) to provide that for each draw down made by the Company under the CL Agreement, the Buyer shall be entitled to receive two types of warrants: A warrants and B warrants, with the A warrants exercisable at any time between 6 and 12 months after issuance for an exercise price per share equal to 1.25 times the average of the closing prices of the 3 trading days preceding the draw down, and the B warrants exercisable at any time between 6 and 24 months after issuance for an exercise price per share equal to 1.5 times the average of the closing prices of the 5 trading days preceding the draw down, and that the number of each of the A warrants and the B warrants issued will be equal to the draw down amount divided by the average of the closing prices of the 3 trading days preceding the draw down, and that these amended terms will apply in respect of all draw downs, including drawdowns made prior to the date of the amendment. On April 12, 2021, the parties to the CL Agreement amended the agreement, so that (i) the annual interest on the Notes should be changed to nine percent (9%) applicable from January 1, 2021, (ii) the Company shall repay the loans at the time it consummates an investment of at least $5 million in the Company’s securities, and (iii) the exercise prices of each of the A warrants and B warrants be modified to $0.10 per share, and the term of the warrants be extended by one (1) year for the A warrants and B warrants. Conversion feature In accordance with ASC 815-15-25 the conversion feature was considered embedded derivative instrument, and is to be recorded at its fair value separately from the convertible notes, within current liabilities in the Company’s balance sheet. The conversion component is then marked to market each reporting period with the resulting gains or losses shown in the statements of operations. The fair value of the conversion feature (hereafter “Convertible Component”) was estimated using the Monte Carlo Simulation Model to compute the Convertible Component’s fair value. The assumptions used to perform the Monte-Carlo simulation model were consistent with those utilized in the Company’s Black-Scholes valuation for stock options are detailed below: June 12, 2020 December 31, 2020 Expected volatility (%) 64.71 % 164.43 % Risk-free interest rate (%) 0.18 % 0.1 % Expected dividend yield 0.0 % 0.0 % Contractual term (years) 1.5 0.95 Conversion price (* ) (* ) Underlying share price (U.S. dollars) 0.21 0.045 Convertible notes amount 1,275,204 1,275,204 Fair value of the conversion feature (U.S. dollars) 285,028 381,147 (*) the conversion price is 85% of the share price, during the period of 5 days preceding the conversion date. Warrants As mentioned above, as part of the Amendment, the Company issued the Buyer 5,589,172 A warrants and 5,589,172 B warrants to purchase a total of 11,178,344 shares of Common Stock of the Company. The fair value of such warrants as of the drawdowns dates was estimated at $301,665 using the Black-Scholes option-pricing model and is presented within the consolidated statements of changes in shareholders equity (deficit). The following are the data and assumptions used: Warrants A Common Stock price 0.21 Expected volatility 65.31 % Expected term 1 years Risk free rate 0.17 % Expected dividend yield 0 % Warrants B Common Stock price 0.21 Expected volatility 68.73 % Expected term 2 years Risk free rate 0.19 % Expected dividend yield 0 % Convertible Notes The drawdowns notice amount, net of the Conversion Component and the warrants amounts (hereafter “Convertible notes”), is $580,925 as of the agreement date. The convertible notes are accounted for according to the effective interest method.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Shareholders' Equity	NOTE 6 – SHAREHOLDERS’ EQUITY Description of the rights attached to the Shares in the Company: Common Stock: Each share of Common Stock entitles the holder to one vote, either in person or by proxy, at meetings of stockholders. The holders of Common Stock are not permitted to vote their shares cumulatively. Accordingly, the holders of the Company’s Common Stock who hold, in the aggregate, more than fifty percent of the total voting rights can elect all of the directors and, in such event, the holders of the remaining minority shares will not be able to elect any of such directors. The vote of the holders of a majority of the issued and outstanding shares of Common Stock entitled to vote thereon is sufficient to authorize, affirm, ratify or consent to such act or action, except as otherwise provided by law. Transactions: On January 29, 2020, holders of 10,344,828 redeemable convertible Series A Preferred Stock, converted their shares into 10,344,828 shares of Common Stock . See also Note 9 below. The terms of the transaction for the issuance of 893,699,276 shares of Common Stock in total are described in Note 1 above. During February and March 2020, the Company issued 432,996,555 shares of Common Stock, par value $0.0001, to investors in respect of the transaction described in Note 1 above, for a total consideration of $45 thousand, and on November 12, 2020 , the Company issued the remaining 445,702,721 shares of Common Stock pursuant to the terms of the transaction for the issuance of 893,699,276 shares of Common Stock in total are described in Note 1 above. On March 5, 2020 the Company issued 15,000,000 shares of Common Stock to its legal advisor in respect of legal consulting services, with respect to the Citrine Global Transaction as well as other legal services, as agreed between the parties, which, as of December 31, 2020, is expected to be provided until February 28, 2021. The Company estimated the fair value of the shares issued based on the share price at the grant date at $4,785 thousand, of which $3,751 thousand were recorded as share based compensation expense in the year ended December 31, 2020, and the remaining was recorded as prepaid share based payment. On May 14, 2020 the Company amended its Certificate of Incorporation to reflect the increase of its authorized capital by one billion shares of Common Stock. On November 11, 2020, the Company issued additional 13,222,082 shares of Common Stock to its legal advisor pursuant to the above agreement. The Company estimated the fair value of the shares issued based on the share price at the grant date at $4,218 thousand, of which $2,109 thousand were recorded as share based compensation expense in the year ended December 31, 2020, and the remaining was recorded as prepaid share based payment. The prepaid services will be expensed over the attribution period of the remaining legal consulting services. Such expense is included in the Marketing, general and administrative expenses within the condensed consolidated statements of operations and comprehensive loss. On November 11, 2020, the Company issued 1,411,104 shares of Common Stock to its Chief Financial Officer. The Company estimated the fair value of the shares issued based on the share price at the grant date at $155 thousand and recorded a share based compensation expense in the year ended December 31, 2020. On October 8, 2020, the Board approved a reverse stock split of the Company’s authorized, issued and outstanding shares of Common Stock, at a ratio between 1-for-40 to 1-for-100, subject to the approval of the Company’s stockholders (the “Reverse Stock Split”). The final ratio of the Reverse Stock Split will be determined by the Board at a later date. Since such reverse stock split was not approved yet as of the approval date of these financial statements, it is not reflected in any share information disclosed within these financial statements. On November 8, 2020, the Board approved an amendment to its Certificate of Incorporation to remove from its authorized capital stock of the Company the fifty million (50,000,000) shares of undesignated Preferred Stock, subject to the approval of the Company’s stockholders. No shares of Preferred Stock are currently outstanding, and such removal and cancellation would remove the authority of the Board or any authorized committee thereof to provide for the issuance of shares of Preferred Stock without further approval of the Company’s stockholders.

Stock Options

Stock Options	12 Months Ended
	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock Options	NOTE 7 – STOCK OPTIONS During March 2017, the Company granted to certain non-employees options to purchase 521,065 of the Company’s Common Stock for an exercise price of $0.0001 per share. The options granted were fully vested on the date of the grant and exercisable into the Company’s Common Stock at a 1:1 ratio for 5 years from the date of the grant. These options were waived and cancelled in the first quarter of 2020 in connection with the Citrine Global Transaction. The following table presents the Company’s stock option activity for employees and directors of the Company for the year ended December 31, 2020: Number of Options Weighted Average Exercise Price Outstanding at December 31, 2019 521,065 0.0011 Granted - - Exercised - - Forfeited or expired (474,303 ) 0.0011 Outstanding at December 31, 2020 46,762 0.0011 Number of options exercisable at December 31, 2020 46,762 0.0011

Agreements With Intelicanna Ltd

Agreements With Intelicanna Ltd	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Agreements With Intelicanna Ltd	NOTE 8 – AGREEMENTS WITH INTELICANNA LTD On May 31, 2020, the Company entered into a strategic partnership with Intelicanna Ltd., an Israeli medical cannabis company listed on the Tel Aviv Stock Exchange with ticker symbol INTL (“Intelicanna”), via a share exchange agreement (the “Share Exchange Agreement”) and an agreement for future issuance of shares( the “Agreement for Future Issuance of Shares”). The Share Exchange Agreement provides that (i) the number of shares each party issues to the other will be calculated by dividing $500 thousand by the volume weighted average price (VWAP) of the issuing party’s shares in the three trading days preceding the signing of the agreement, (ii) the issuance by Intelicanna will take place upon, and subject to, receipt of approval from the Tel Aviv Stock Exchange, and the issuance by the Company will follow immediately thereafter, and (iii) the parties may not sell the shares within the first six months after issuance, and thereafter the parties may sell the shares issued to them if the shares become registered through a prospectus approved by the relevant securities authority, or under an exemption provided by applicable securities law, subject to a limit on the number of shares either party may sell per day. The Agreement for future Issuance of Shares provides that a fall in a share price of a party, not exceeding 20%, measured six months after issuance of shares by both parties pursuant the Share Exchange Agreement, will be offset by the issuance of additional shares to the other party to bring up to $500 thousand the total value of the shares issued to the other party. On September 17, 2020 the Company issued to Intelicanna 2,143,470 shares of Common Stock in exchange for 619,589 of Intelicanna’s ordinary shares. The Company measures its investment in Intelicanna at fair value through profit or loss at level 2. The fair value reflects the value of Intelicanna’s stock price less discounts for lack of marketability since the parties may not sell the shares within the first six months after issuance. During the period, the change in traded securities’ fair value was in the amount of approximately $50 thousand. The fair value of such shares exchange agreement was estimated using the Black-Scholes option-pricing model and is presented among current liabilities within the Company’s condensed consolidated balance sheet. The following are the data and assumptions used as of the balance sheet date related to future potential issuance of shares as describe above for potential fall in share price of a party, not exceeding 20%: Derivative related to Intelicanna’s shares December 31, 2020 Common Stock price 0.83 Expected volatility 57.61 % Conversion price (U.S. dollars) 0.64 Expected term 3.1 months Risk free rate 0.09 % Expected dividend yield 0 % Fair value of the derivative (U.S. dollars) 27,975 Derivative related to Citrine Global’s shares December 31, 2020 Common Stock price 0.046 Expected volatility 125.19 % Conversion price (U.S. dollars) 0.2 Expected term 3.1 months Risk free rate 0.09 % Expected dividend yield 0 % Fair value of the derivative (U.S. dollars) (99,697 ) Furthermore, on June 25, 2020, the Israeli Subsidiary entered into a services agreement with Intelicanna to provide business development and consulting services to Intelicanna, including assistance with raising financing (the “Services Agreement”) (references in this paragraph to the Company include the Israeli Subsidiary). The terms of the Services Agreement include: (1) the Company will, for a period of 18 months, assist Intelicanna to raise up to NIS 15 million for Intelicanna’s working capital purposes, whether through issuance of convertible securities or any other means; all sums raised must be approved in advance by the Company, and in accordance with a business plan presented to the Company from time to time; the Company will have no obligation under the Services Agreement to invest in Intelicanna, and no liability if its efforts to source financing for Intelicanna are unsuccessful; (2) in the event Intelicanna raises funds through assistance from the Company, the Company will be entitled to (i) cash consideration equal to 5% of any amount raised, whether directly from the Company, or from any of its affiliates or any unrelated third party, and (ii) options to acquire a number of shares of Intelicanna equal to 5% of the amount raised divided by the Exercise Price; the “Exercise Price” will be the price per share at which the amount was raised, or if it was not raised through issuance of shares, the price per share at which Intelicanna last raised funds through issuance of shares; and (3) for one or more periods of at least 90 days, each time at Intelicanna’s request which the Company may accept or decline at its discretion, the Company will provide business development and strategy-building services, including: consulting on strategy and business plan; assistance defining financing needs; helping identify ways to develop potential sources of finance; and ongoing consulting support to Intelicanna’s management team and board. Intelicanna will pay the Company a fee of NIS 2,500 per day for such services. Also on June 25, 2020, to assist Intelicanna to raise the first NIS 1 million towards the up to NIS 15 million mentioned in the Services Agreement, the Company and the Israeli Subsidiary entered into an agreement to grant Intelicanna NIS 1 million in cash (approximately USD 290 thousand) in direct financing for working capital purposes. The financing will bear 6% annual interest and Intelicanna will make additional payments equalling 6% of its gross revenues between the date the financing is received and the date Intelicanna’s aggregate gross revenues thereafter equal NIS 2 million. If the total of the 6% interest plus the additional payments would result in a return of less than 12% in the year to the Company, the interest will be increased to bring the total return to 12%. Every three months Intelicanna must pay the interest, and after 12 months, it must repay the capital, plus the total of the additional payments due, plus any outstanding interest, and it must pay interest of 2% per month on any late payments, provided however that until the foregoing obligations are paid in full Intelicanna must pay 50% of its gross revenues to the Company upon receipt. If Intelicanna does not pay all amounts due within 18 months, it shall, at the Company’s option, issue to the Company a number of its shares equal to NIS 1.5 million divided by the lower of (i) VWAP of the three trading days prior to the lapse of the 18 months, and (ii) VWAP of the three trading days prior to the signing of the financing agreement. The financing must be paid by the Company to Intelicanna within 30 days of signing the financing agreement, subject to completion of due diligence to the Company’s satisfaction and to Intelicanna receiving a commercial growing license. On July 9, 2020, the Company transferred to Intelicanna NIS 500 thousand (approximately $145 thousand) on account of the above loan. The Company elected the fair value option to account for the short-term loan. See also Note 12B below. Ilanit Halperin, a director and the Chief Financial Officer of the Company, is also the Chief Financial Officer of Intelicanna. Doron Birger, a director at the Company, is also the chairman of the board of directors of Intelicanna, effective April 12, 2021.

Related Parties

Related Parties	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Parties	NOTE 9 – RELATED PARTIES a. On November 11, 2014, the Company entered into a consulting agreement with Mr. Yossef De-Levy (“Mr. De-Levy”), then a member of the Board. Pursuant to the consulting agreement, Mr. De-Levy received a gross monthly amount of NIS 5,000, which was updated on May 31, 2015, to NIS 10,000 (approximately $2,900). The foregoing payment was in addition to, and independent of, the fee that Mr. De-Levy was entitled to receive for continued services as a member of the Board. In March 2019 and April 2019, the Company entered into an amendment to the consulting agreement, according to which the monthly retainer was waived commencing on November 15, 2018, through December 31, 2019. The Company recorded the expense against equity. The consulting agreement was terminated on March 16, 2020, and the monthly retainer from December 31, 2019, was waived. b. On December 31, 2015, the Company entered into a consulting agreement with Zvi Yemini and with his affiliated entity Y.M.Y Industry Ltd. (“YMY”). Zvi Yemini served as Chairman of the Board until August 13, 2019, and as a Board member until November 14, 2019, and as Chief Executive Officer from February 15, 2019, until November 14, 2019. Pursuant to the consulting agreement, Mr. Yemini received a gross monthly amount of NIS 24,000 (approximately $6,200). The foregoing payment was in addition to, and independent of, the fee that Mr. Yemini was entitled to receive for continued services as a member of the Board. On February 22, 2017, the Company signed an amendment to the original agreement with Mr. Yemini and YMY. Pursuant to the amendment, Mr. Yemini’s monthly payment was increased to NIS 45,000 (approximately $13,000) starting in February 2017. In March 2019 and April 2019, the Company entered into an amendment to the consulting agreement, according to which the monthly retainer was waived commencing on November 15, 2018 through December 31, 2019. The consulting agreement was terminated on November 14, 2019, which was also the effective date of Zvi Yemeni’s resignation as a director of the Company and of his resignation as an officer of the Company. c. On July 31, 2016, the Company entered into a consulting agreement with Mr. Traistman, who was a member of the Board until February 27, 2020, including Chairman of the Board from August 13, 2019, and principal executive officer of the Company from November 14, 2019 until February 27, 2020. Pursuant to the consulting agreement, Mr. Traistman received a gross monthly amount of NIS 10,000 (approximately $2,900). In March 2019 and April 2019, the Company entered into an amendment to the consulting agreement, according to which the monthly retainer was waived commencing on November 15, 2018 through December 31, 2019. The consulting agreement was terminated on March 16, 2020 and the monthly retainer from December 31, 2019 was waived. d. On December 31, 2017, the Company entered into a consulting agreement with Mr. Ran Tuttnauer, a member of the advisory Board. Pursuant to the consulting agreement, Mr. Tuttnauer received a gross monthly amount of $2,000. In March 2019, the Company entered into an amendment to the consulting agreement, pursuant to which the monthly retainer was waived commencing on November 15, 2018. In April 2019 the consulting agreement was terminated. e. On April 28, 2019, the Company entered into a form of Securities Purchase Agreement with each of Y.M.Y. Industry Ltd. (“YMY”), Traistman Radziejewski Fundacja Ltd. (“TRF”) and Microdel Ltd. (together with YMY and TRF, the “Investors”) relating to an offering of an aggregate of 1,229,508 shares of the Company’s Common Stock at a purchase price of $0.183 per share for aggregate gross proceeds of approximately $225,000. In addition, the Company granted the Investors an option, for a period of twelve months, to purchase up to an additional 375,001 shares of Common Stock at a price per share of $0.60, for additional aggregate consideration of $225,000. The closing of the offering took place on April 29, 2019. Such option expired during the second quarter of 2020. f. On August 20, 2019, the Company entered into an additional form of securities purchase agreement with YMY and TRF, relating to an offering of an aggregate of 8,275,862 shares of the Company’s newly designated Series A Convertible Preferred Stock at a purchase price of $0.029 per share for aggregate gross proceeds of approximately $240,000. In addition, the Company granted YMY and TRF an option, for a period of twelve months, to purchase an additional 400,000 Series A Convertible Preferred Stock, in the aggregate, at a price per share of $0.60, for additional aggregate consideration of $240,000. The closing of the offering took place on August 29, 2019. Such option expired during the second quarter of 2020. g. On October 23, 2019, Novomic appointed Idan Traitsman to serve as the Chief Executive Officer of Novomic, effective immediately. In connection with Idan Traitsman’s appointment, the Company agreed to pay Idan Traitsman a monthly salary of NIS 10,000 (approximately $2,800) plus VAT. Idan Traistman is the brother of Mr. Traistman, who served as a director of the Company until February 27, 2020. h. On November 17, 2019, the Company entered into a form of securities purchase agreement with YMY and TRF, relating to an offering of an aggregate of 2,068,966 shares of the Company’s newly designated Series A Convertible Preferred Stock at a purchase price of $0.029 per share for aggregate gross proceeds of approximately $60,000 in 2019 and 931,034 shares of the Company’s newly designated Series A Convertible Preferred Stock at a purchase price of $0.029 per share for aggregate gross proceeds of approximately $27,000 in 2020. In addition, the Company granted YMY and TRF an option, for a period of twelve months, to purchase up to an additional 100,000 Series A Convertible Preferred Stock, in the aggregate, at a price per share of $0.60, for additional aggregate consideration of $60,000 with respect to the 2019 purchase and 45,000 Series A Convertible Preferred Stock, in the aggregate, at a price per share of $0.60, for additional aggregate consideration of $27,000 with respect to the 2020 purchase. Such option expired during the second quarter of 2020. i. Commencing February 2020, Ora Elharar Soffer, CEO and chairperson of the Board, is entitled to a monthly fee of $20,000 and certain reimbursements for traveling, lodging and other expenses on behalf of the Company. As of December 31, 2020, an amount of $210,200 represent compensation earned by Ora Elharar Soffer during the year ended December 31, 2020 but that was deferred until the Company consummated an investment of at least $1.8 million in the Company’s securities. j. Commencing February 2020, Ilanit Halperin, director, and Ilan Ben-Ishay, director, are each entitled to a monthly fee of $3,500 and certain reimbursements for traveling lodging and vehicle expenses on behalf of the Company. As of December 31, 2020, an amount of $34,109 represent compensation earned by Ilan Ben-Ishay during the year ended December 31, 2020 but that was deferred until the Company consummated an investment of at least $1.8 million in the Company’s securities. k. Commencing May 2020, Ilanit Halperin, CFO of the Company, is entitled to a monthly fee of an additional $3,500, resulting in an aggregate monthly fee of $7,000. As of December 31, 2020, an amount of $66,164 represent compensation earned by Ilanit Halperin during the year ended December 31, 2020 but was deferred until the Company consummated an investment of at least $1.8 million in the Company’s securities. l. Refer also to Note 3 and Note 8 regarding transactions with Nanomedic and Intelicanna, respectively. m. Refer also to Note 1 regarding establishment of a Cannovation Center. n. On August 4, 2020, the Board of directors of the Company approved for the Company and/or the Israeli Subsidiary (references in this paragraph to the Company include the Israeli Subsidiary) to proceed with preparations for investing iBOT. iBOT has a manufacturing facility for a wide range of botanical formulations, and part of its strategy is to combine this with hemp and CBD. The board gave its approval, subject to agreement of definitive terms and receipt of all necessary corporate and other approvals, for a proposed transaction in which (1) the Company would have an option to make one or more investments during a period of 12 months in an aggregate amount of up to $1 million (one million U.S. dollars); (2) the investments may be through loans, direct equity purchases, or other means, and would be based on milestones; and (3) iBOT would grant the Company a 25% discount in its next fundraising. In addition, the Board approved for the Company to proceed with preparations for entering a services agreement with iBOT pursuant to which the Company would provide consulting and other services to iBOT. iBOT is controlled by an affiliate of the Company. As of the date of these financial statements, such agreements have not yet been signed and the Company is still in the process of examining the cooperation and investment in iBOT.

Income Tax

Income Tax	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Tax	NOTE 10 – INCOME TAX A. United States resident companies are taxed on their worldwide income for corporate income tax purposes at a statutory rate of 21%. No further taxes are payable on this profit unless that profit is distributed. If certain conditions are met, income derived from foreign subsidiaries is tax exempt in the United States under applicable tax treaties to avoid double taxation. Income of the Israeli Subsidiary is taxable from 2018 and onwards, at corporate tax rate of 23%. The Company and its Israeli Subsidiary have not received final tax assessments since the Israeli Subsidiary’s inception. As of December 31, 2020, the Company and the Israeli Subsidiary have carryforward losses for tax purposes of approximately $1,795,036 and $53,019, respectively, which can be offset against future taxable income, if any. As of December 31, 2019, Novomic’s carryforward tax losses amounted to $7,725 thousand. B. The following is reconciliation between the theoretical tax on pre-tax income, at the tax rate applicable to the Company (federal tax rate) and the tax expense reported in the financial statements: Year ended December 31 2020 2019 U.S. Dollars Pretax loss 8,639,159 1,874,135 Federal tax rate 21 % 21 % Income tax computed at the ordinary tax rate 1,814,223 393,568 Non-deductible expenses 874 6,831 Stock-based compensation 1,558,520 2,618 Fair value adjustments 41,468 - Tax in respect of differences in corporate tax rates (1,060 ) (32,463 ) Losses and timing differences in respect of which no 214,421 416,582 - - C. Deferred taxes result primarily from temporary differences in the recognition of certain revenue and expense items for financial and income tax reporting purposes. Significant components of the Company’s future tax assets are as follows: Year ended December 31 Composition of deferred tax assets: 2020 2019 Research and development credit carry forwards - 41,417 Provision for slow moving inventory - 40,522 Non capital loss carry forwards 362,385 1,959,070 Valuation allowance (362,385 ) (2,041,009 ) - -

Loss Per Ordinary Share

Loss Per Ordinary Share	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Loss Per Ordinary Share	NOTE 11 – LOSS PER ORDINARY SHARE Basic loss per share is computed by dividing net loss by the weighted average number of shares outstanding during the year. The weighted average number of shares of Common Stock used in computing basic and diluted loss per ordinary share for the years ended December 31, 2020 and 2019, are as follows: Year ended December 31 2020 2019 Number of shares Weighted average number of shares of Common Stock outstanding attributable to ordinary shareholders 476,622,892 37,473,278 Total weighted average number of shares of Common Stock related to outstanding options, excluded from the calculations of diluted loss per share (*) 46,762 46,762 (*) The effect of the inclusion of option and convertible loans in 2020 and 2019 is anti-dilutive.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 12 – SUBSEQUENT EVENTS a. On March 31, 2021, the loan provided to Intelicanna by the Company was repaid with the 12% interest. b. On April 12, 2021, the parties to the CL Agreement amended the agreement, so that (i) the annual interest on the Notes should be changed to nine percent (9%) applicable from January 1, 2021, (ii) the Company shall repay the loans at the time it consummates an investment of at least $5 million in the Company’s securities, and (iii) the exercise prices of each of the A Warrants and B Warrants be modified to $0.10 per share, and the term of the warrants be extended by one (1) year for the A Warrants and B Warrants.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Basis of Presentation (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of Citrine Global, and its subsidiary, CTGL – Citrine Global Israel Ltd. All significant intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates include fair value estimates of derivative liabilities and assets discussed in Notes 5 and 8, as well as the estimated service period related to share based payment to the Company’s legal advisor (refer to Note 6). Actual results could differ from those estimates.
Functional Currency and Foreign Currency Translation and Transactions	Functional Currency and Foreign Currency Translation and Transactions. Effective May 14, 2020, the Company adopted the U.S. dollar as its functional currency. Prior to May 14, 2020, the functional currency of the Company was the New Israeli Shekel (“NIS”). The change in functional currency of the Company is due to the increased exposure to the U.S. dollar as a result of Sale of the Novomic as described in Note 4 below. Therefore, the currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the U.S. dollar. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Non-monetary assets and liabilities are translated using the historical rate on the date of the transaction. All exchange gains or losses arising from translation of these foreign currency transactions are included in net loss for the year.
Cash and Cash Equivalents	Cash and cash equivalents Cash equivalents are short-term highly liquid investments which include short term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawals or use that are readily convertible to cash with maturities of three months or less as of the date acquired.
Property, Plant and Equipment, net	Property, plant and equipment, net 1. Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. When an asset is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected in the Statements of Operations and Comprehensive Loss. 2. Rates of depreciation: % Computers and software 33 Electronic equipment 15 Office furniture and equipment 7 – 6 Leasehold improvements 10 Machinery and equipment mainly 20
Trading Securities and Short-term Loan Measured at Fair Value	Trading securities and short-term loan measured at fair value The Company accounts for its investments in trade securities in accordance with Accounting Standards “ASC”) No. 320, “Investments—Debt and Equity Securities.” The Company determines the appropriate classification of its investments in trading securities at the time of purchase and re-evaluates the fair value at each balance sheet date. As of December 31, 2020, all of the Company’s investments in trading securities are classified as held for trade (see also Note 8). Therefore, the Company’s trading securities are recorded at fair value on the balance sheet as well as the short-term loan measured at fair value according to the company’s election. Changes in fair value of trading securities and short-term loan are recorded in financing income (expenses), net in the consolidated statement of operations.
Investments Valued Under the Measurement Alternative	Investments valued under the measurement alternative The Company’s investments as described in Notes 3 and 4 are valued under the measurement alternative include equity securities in other proprietary investments for which the Company does not have significant influence and fair value is not readily determinable. Accounting Standard Update (“ASU”) 2016-01 requires equity securities to be recorded at cost and adjusted to fair value at each reporting period. However, the guidance allows for a measurement alternative, which is to record investments at cost, less impairment, if any, and subsequently adjust for observable price changes of identical or similar investments of the same issuer. Due to the lack of readily determinable fair values for such investments, for which the Company does not have significant influence, the Company accounts for these investments under the measurement alternative at cost, less impairment. The Company performs qualitative impairment assessments on its investments recorded under the measurement alternative.
Impairment of Long-lived assets	Impairment of long-lived assets The Group’s long-lived assets are reviewed for impairment in accordance with ASC Topic 360, “Property, Plant and Equipment”, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value.
Derivatives	Derivatives Derivative instruments are recognized on the balance sheet at their fair value, with changes in the fair value recognized as a component of financial expenses, net in the statements of income. Once determined, derivative liabilities and assets are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.
Deferred Income Taxes	Deferred income taxes The Company accounts for income taxes in accordance with ASC Topic 740, “Income Taxes”. Accordingly, deferred income taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and the tax bases of assets and liabilities under the applicable tax law. Deferred tax balances are computed using the enacted tax rates expected to be in effect when these differences reverse. Valuation allowances in respect of deferred tax assets are provided for, if necessary, to reduce deferred tax assets to amounts more likely than not to be realized. The Company accounts for uncertain tax positions in accordance with ASC Topic 740-10, which prescribes detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in an enterprise’s financial statements. According to ASC Topic 740-10, tax positions must meet a more-likely-than-not recognition threshold. The Company’s accounting policy is to classify interest and penalties relating to uncertain tax positions under income taxes, however the Company did not recognize such items in its fiscal 2020 and 2019 financial statements and did not recognize any liability with respect to an unrecognized tax position in its balance sheets.
Revenue Recognition	Revenue recognition Revenues are recognized when delivery has occurred and there is persuasive evidence of an agreement, the fee is fixed or determinable and collection of the related receivables is reasonably assured, and no further obligations exist. Revenues from sales of products are recognized when title and risk and rewards for the products are transferred to the customer.
Research and Development Expenses	Research and development expenses Research and development costs consist primarily of employee compensation expenses, materials, laboratory supplies, costs s for facilities and equipment. Expenditures for research and development are expensed as incurred.
Basic and Diluted Loss Per Ordinary Share	Basic and diluted loss per ordinary share Basic loss per share of Common Stock is computed by dividing the loss for the period applicable to holders of shares of Common Stock, by the weighted average number of shares of Common Stock outstanding during the period. Securities that may participate in dividends with the shares of Common Stock (such as the convertible Preferred Stock) are considered in the computation of basic loss per share under the two-class method. However, in periods of net loss, only the convertible Preferred Stock are considered, since such shares have a contractual obligation to share in the losses of the Company. In computing diluted loss per share, basic loss per share is adjusted to reflect the potential dilution that could occur upon the exercise of potential shares. Accordingly, in periods of net loss, no potential shares are considered.
Stock-Based Compensation	Stock-based compensation The Company measures and recognizes the compensation expense for all equity-based payments based on their estimated fair values in accordance with ASC 718, “Compensation-Stock Compensation”. Share-based payments including grants of stock options are recognized in the statement of comprehensive loss as an operating expense based on the fair value of the award at the date of grant. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model. The Company has expensed compensation costs, net of estimated forfeitures, applying the accelerated vesting method, over the requisite service period or over the implicit service period when a performance condition affects the vesting, and it is considered probable that the performance condition will be achieved.
Fair Value	Fair value Fair value of certain of the Company’s financial instruments including cash, accounts receivable, accounts payable, accrued expenses, and other accrued liabilities approximate cost because of their short maturities. The Company measures and reports fair value in accordance with ASC 820, “Fair Value Measurements and Disclosure” defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles and expands disclosures about fair value measurements. Fair value, as defined in ASC 820, is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of an asset should reflect its highest and best use by market participants, principal (or most advantageous) markets, and an in-use or an in-exchange valuation premise. The fair value of a liability should reflect the risk of nonperformance, which includes, among other things, the Company’s credit risk. Valuation techniques are generally classified into three categories: the market approach; the income approach; and the cost approach. The selection and application of one or more of the techniques may require significant judgment and are primarily dependent upon the characteristics of the asset or liability, and the quality and availability of inputs. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 also provides fair value hierarchy for inputs and resulting measurement as follows: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities; and Level 3: Unobservable inputs for the asset or liability that are supported by little or no market activity, and that are significant to the fair values. Fair value measurements are required to be disclosed by the Level within the fair value hierarchy in which the fair value measurements in their entirety fall. Fair value measurements using significant unobservable inputs (in Level 3 measurements) are subject to expanded disclosure requirements including a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (i) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings, and a description of where those gains or losses included in earning are reported in the statement of operations. The Company’s financial assets and liabilities that are measured at fair value on a recurring basis by level within the fair value hierarchy are as follows: Balance as of December 31, 2020 Level 1 Level 2 Level 3 Total Trading securities (Note 8) - 521,615 - 521,615 Short-term loan measured at fair value (Note 8) - - 165,185 165,185 Total assets - 521,615 165,185 686,800 Liabilities: Fair value of convertible component in convertible notes (Note 5) - - 381,147 381,147 Fair Value of forward option (Note 8) - - 71,722 71,722 Total liabilities - - 452,869 452,869 The following table presents the changes in fair value of the level 3 liabilities for the year ended December 31, 2020: Changes in Fair value Assets: Outstanding at January 1, 2020 - Fair value of issued level 3 assets 145,000 Changes in fair value 20,185 Outstanding at December 31, 2020 165,185 Liabilities: Outstanding at January 1, 2020 - Fair value of issued level 3 liability 350,608 Changes in fair value 102,261 Outstanding at December 31, 2020 452,869
Concentrations of Credit Risk	Concentrations of credit risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents as well as certain other current assets that do not amount to a significant amount. Cash and cash equivalents, which are primarily held in Dollars and New Israeli Shekels, are deposited with major banks in Israel and United States. Management believes that such financial institutions are financially sound and, accordingly, minimal credit risk exists with respect to these financial instruments. The Company does not have any significant off-balance-sheet concentration of credit risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.
Contingencies	Contingencies The Company records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Accounting Pronouncements Adopted in 2020 In June 2016, the Financial Accounting Standards Board (“FASB”) issued an ASU that supersedes the existing impairment model for most financial assets to a current expected credit loss model. The new guidance requires an entity to recognize an impairment allowance equal to its current estimate of all contractual cash flows the entity does not expect to collect. The Company adopted this guidance effective January 1, 2020, with no material impact on its consolidated financial statements In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. The guidance became effective on January 1, 2020, including interim periods within that year and requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. Under the modified retrospective method of adoption, prior year reported results are not restated. The Company has performed its analysis of the impact on its financial instruments that are within the scope of this guidance and has concluded that there was no material impact to its consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework — Changes to the Disclosure Requirements for Fair Value Measurement” (“ASU No. 2018-13”) as part of the FASB’s broader disclosure framework project. ASU No. 2018-13 removes, modifies and adds certain disclosures, providing greater focus on requirements that clearly communicate the most important information to the users of the financial statements with respect to fair value measurements. The Company’s adoption of ASU No. 2018-13 as of January 1, 2020 did not have a material impact on the Company’s consolidated financial statements. Recently Issued Accounting Pronouncements Not Yet Adopted In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes” (“ASU 2019-12”). The amendments in this ASU simplify the accounting for income taxes, eliminates certain exceptions to the general principles in Topic 740 and clarifies certain aspects of the current guidance to improve consistent application among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021 and interim periods within annual periods beginning after December 15, 2022, though early adoption is permitted, including adoption in any interim period for which financial statements have not yet been issued. This standard is not expected to have a material impact to the Company’s consolidated financial statements after evaluation. In August 2020, the FASB issued ASU No. 2020-06, “Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”. ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible Preferred Stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current U.S. GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective for public companies for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU 2020-06 will have on the Company’s consolidated financial statement presentation or disclosures. Other new pronouncements issued but not effective as of December 31, 2020 are not expected to have a material impact on the Company’s consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies and Basis of Presentation (Tables)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Schedule of Rate of Depreciation of Property Plant and Equipment	2. Rates of depreciation: % Computers and software 33 Electronic equipment 15 Office furniture and equipment 7 – 6 Leasehold improvements 10 Machinery and equipment mainly 20
Schedule of Financial Assets and Liabilities Measured at Fair Value On a Recurring Basis	The Company’s financial assets and liabilities that are measured at fair value on a recurring basis by level within the fair value hierarchy are as follows: Balance as of December 31, 2020 Level 1 Level 2 Level 3 Total Trading securities (Note 8) - 521,615 - 521,615 Short-term loan measured at fair value (Note 8) - - 165,185 165,185 Total assets - 521,615 165,185 686,800 Liabilities: Fair value of convertible component in convertible notes (Note 5) - - 381,147 381,147 Fair Value of forward option (Note 8) - - 71,722 71,722 Total liabilities - - 452,869 452,869
Schedule of Changes in Fair Value of Liabilities	The following table presents the changes in fair value of the level 3 liabilities for the year ended December 31, 2020: Changes in Fair value Assets: Outstanding at January 1, 2020 - Fair value of issued level 3 assets 145,000 Changes in fair value 20,185 Outstanding at December 31, 2020 165,185 Liabilities: Outstanding at January 1, 2020 - Fair value of issued level 3 liability 350,608 Changes in fair value 102,261 Outstanding at December 31, 2020 452,869

Sale of Novomic (Tables)

Sale of Novomic (Tables)	12 Months Ended
	Dec. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]
Summary of Deconsolidation of a Subsidiary	The following table summarizes the assets and liabilities of Novomic as of the deconsolidation date: Cash and cash equivalents 13,810 Working capital (excluding cash and cash equivalents), net (deficit) (217,111 ) Long term assets 155,988 Long term liabilities (5,017 ) (52,330 ) Amounts received - GAIN FROM DECONSOLIDATION OF A SUBSIDIARY $ 52,330

Convertible Notes (Tables)

Convertible Notes (Tables)	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Schedule of Fair Value of Convertible Feature using Valuation Assumptions	The assumptions used to perform the Monte-Carlo simulation model were consistent with those utilized in the Company’s Black-Scholes valuation for stock options are detailed below: June 12, 2020 December 31, 2020 Expected volatility (%) 64.71 % 164.43 % Risk-free interest rate (%) 0.18 % 0.1 % Expected dividend yield 0.0 % 0.0 % Contractual term (years) 1.5 0.95 Conversion price (* ) (* ) Underlying share price (U.S. dollars) 0.21 0.045 Convertible notes amount 1,275,204 1,275,204 Fair value of the conversion feature (U.S. dollars) 285,028 381,147 (*) the conversion price is 85% of the share price, during the period of 5 days preceding the conversion date.
Summary of Warrants	The following are the data and assumptions used: Warrants A Common Stock price 0.21 Expected volatility 65.31 % Expected term 1 years Risk free rate 0.17 % Expected dividend yield 0 % Warrants B Common Stock price 0.21 Expected volatility 68.73 % Expected term 2 years Risk free rate 0.19 % Expected dividend yield 0 %

Stock Options (Tables)

Stock Options (Tables)	12 Months Ended
	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Stock Option Activity	The following table presents the Company’s stock option activity for employees and directors of the Company for the year ended December 31, 2020: Number of Options Weighted Average Exercise Price Outstanding at December 31, 2019 521,065 0.0011 Granted - - Exercised - - Forfeited or expired (474,303 ) 0.0011 Outstanding at December 31, 2020 46,762 0.0011 Number of options exercisable at December 31, 2020 46,762 0.0011

Agreements With Intelicanna L_2

Agreements With Intelicanna Ltd (Tables)	12 Months Ended
	Dec. 31, 2020
Agreements With Intelicanna Ltd Tables Abstract
Schedule of Fair Value of Shares Exchange Agreement	The following are the data and assumptions used as of the balance sheet date related to future potential issuance of shares as describe above for potential fall in share price of a party, not exceeding 20%: Derivative related to Intelicanna’s shares December 31, 2020 Common Stock price 0.83 Expected volatility 57.61 % Conversion price (U.S. dollars) 0.64 Expected term 3.1 months Risk free rate 0.09 % Expected dividend yield 0 % Fair value of the derivative (U.S. dollars) 27,975 Derivative related to Citrine Global’s shares December 31, 2020 Common Stock price 0.046 Expected volatility 125.19 % Conversion price (U.S. dollars) 0.2 Expected term 3.1 months Risk free rate 0.09 % Expected dividend yield 0 % Fair value of the derivative (U.S. dollars) (99,697 )

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Reconciliation of Effective Tax Rate	B. The following is reconciliation between the theoretical tax on pre-tax income, at the tax rate applicable to the Company (federal tax rate) and the tax expense reported in the financial statements: Year ended December 31 2020 2019 U.S. Dollars Pretax loss 8,639,159 1,874,135 Federal tax rate 21 % 21 % Income tax computed at the ordinary tax rate 1,814,223 393,568 Non-deductible expenses 874 6,831 Stock-based compensation 1,558,520 2,618 Fair value adjustments 41,468 - Tax in respect of differences in corporate tax rates (1,060 ) (32,463 ) Losses and timing differences in respect of which no 214,421 416,582 - -
Schedule of Deferred Tax Assets	C. Deferred taxes result primarily from temporary differences in the recognition of certain revenue and expense items for financial and income tax reporting purposes. Significant components of the Company’s future tax assets are as follows: Year ended December 31 Composition of deferred tax assets: 2020 2019 Research and development credit carry forwards - 41,417 Provision for slow moving inventory - 40,522 Non capital loss carry forwards 362,385 1,959,070 Valuation allowance (362,385 ) (2,041,009 ) - -

Loss Per Ordinary Share (Tables

Loss Per Ordinary Share (Tables)	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Loss Per Ordinary Share	The weighted average number of shares of Common Stock used in computing basic and diluted loss per ordinary share for the years ended December 31, 2020 and 2019, are as follows: Year ended December 31 2020 2019 Number of shares Weighted average number of shares of Common Stock outstanding attributable to ordinary shareholders 476,622,892 37,473,278 Total weighted average number of shares of Common Stock related to outstanding options, excluded from the calculations of diluted loss per share (*) 46,762 46,762 (*) The effect of the inclusion of option and convertible loans in 2020 and 2019 is anti-dilutive.

General (Details Narrative)

General (Details Narrative) - USD ($)	Nov. 22, 2020	Aug. 20, 2020	Aug. 04, 2020	Feb. 23, 2020	Jan. 06, 2020	Dec. 31, 2020	Dec. 31, 2019
Accumulated losses						$ (19,241,451)	$ (10,602,292)
Equity investment percentage	50.00%
Description of reverse stock split	On November 22, 2020, certain of the Company's stockholders representing more than 50% of the Company's outstanding share capital (the "Majority Consenting Stockholders") approved an amendment to the Company's Certificate of Incorporation (the "Reverse Stock Split Certificate of Amendment") in order to effect a reverse stock split of the Company's common stock pursuant to a range of between 40-to-1 and 100-to-1 (the "Reverse Stock Split").					On October 8, 2020, the Board approved a reverse stock split of the Company's authorized, issued and outstanding shares of Common Stock, at a ratio between 1-for-40 to 1-for-100, subject to the approval of the Company's stockholders (the "Reverse Stock Split"). The final ratio of the Reverse Stock Split will be determined by the Board at a later date.
Preferred stock shares undesignated	50,000,000
Traistman Radziejewski Fundacja Ltd. [Member]
Percentage of shares sold					90.00%
Capital stock description					Definitive agreements were executed for the sale of 90% of the shares in Novomic Ltd. ("Novomic") to Traistman Radziejewski Fundacja Ltd. ("TRF"), which was completed on May 14, 2020 (the "Novomic Divestment"), and for the issuance and sale of a number of shares equal after the issuance to 95% of the fully diluted capital stock of the Company to Citrine S A L Group, which was amended on February 23, 2020, to provide for the issuance and sale of the shares in stages (the "Citrine Global Transaction"). Shares of the Company were issued and sold in accordance with this amended agreement to Citrine S A L Group on February 27, 2020, March 5, 2020, and, after the Company amended its Certificate of Incorporation to increase its authorized share capital, on November 11, 2020.
Israeli Subsdiary [Member]
Description on agreement terms			On August 4, 2020, the Board of the Company approved for the Company and its Israeli Subsidiary to proceed with preparations for investing in iBOT Israel Botanicals Ltd., an Israeli botanical nutraceutical company ("iBOT"). iBOT has a manufacturing facility for a wide range of botanical formulations, and part of its strategy is to combine this with hemp and cannabidiol ("CBD"). The Board gave its approval, subject to agreement of definitive terms and receipt of all necessary corporate and other approvals, for a proposed transaction in which (1) the Company would have an option to make one or more investments during a period of 12 months in an aggregate amount of up to $1 million; (2) the investments may be through loans, direct equity purchases, or other means, and would be based on milestones; and (3) iBOT would grant the Company a 25% discount in its next fundraising. In addition, the Board approved for the Company to proceed with preparations for entering a services agreement with iBOT pursuant to which the Company would provide consulting and other services to iBOT. iBOT is controlled by an affiliate of the Company. The Company is still in the process of examining the cooperation and investment in iBOT.
The Cannovation Center [Member]
Percentage of shares hold by certain shareholders		60.00%
Maximum [Member]
Capital stock shares issued	1,550,000,000
Minimum [Member]
Capital stock shares issued	1,500,000,000
AR Citrine Agreement [Member]
Percentage of shares sold				95.00%
AR Citrine Agreement [Member] | Second Tranche [Member]
Percentage of shares sold				95.00%
AR Citrine Agreement [Member] | Maximum [Member]
Aggreagate number of common stock shares issued				893,699,276
AR Citrine Agreement [Member] | Maximum [Member] | Initial Tranche [Member]
Aggreagate number of common stock shares issued				452,063,196

Summary of Significant Accoun_4

Summary of Significant Accounting Policies and Basis of Presentation - Schedule of Rate of Depreciation of Property Plant and Equipment (Details)	Dec. 31, 2020
Computers and Software [Member]
Rates of depreciation	33.00%
Electronic Equipment [Member]
Rates of depreciation	15.00%
Office Furniture and Equipment [Member] | Minimum [Member]
Rates of depreciation	6.00%
Office Furniture and Equipment [Member] | Maximum [Member]
Rates of depreciation	7.00%
Leasehold Improvements [Member]
Rates of depreciation	10.00%
Machinery and Equipment [Member]
Rates of depreciation	20.00%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies and Basis of Presentation - Schedule of Financial Assets and Liabilities Measured at Fair Value On a Recurring Basis (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Total assets	$ 3,104,528	$ 256,827
Total Liabilities	1,701,670	$ 367,590
Fair Value, Recurring [Member]
Total assets	686,800
Total Liabilities	452,869
Short-term Loan Measured at Fair Value | Fair Value, Recurring [Member]
Total assets	165,185
Fair Value of Convertible Component in Convertible Notes [Member] | Fair Value, Recurring [Member]
Total Liabilities	381,147
Fair Value of Forward Option [Member] | Fair Value, Recurring [Member]
Total Liabilities	71,722
Trading Securities [Member] | Fair Value, Recurring [Member]
Total assets	521,615
Level 1 [Member] | Fair Value, Recurring [Member]
Total assets
Total Liabilities
Level 1 [Member] | Short-term Loan Measured at Fair Value | Fair Value, Recurring [Member]
Total assets
Level 1 [Member] | Fair Value of Convertible Component in Convertible Notes [Member] | Fair Value, Recurring [Member]
Total Liabilities
Level 1 [Member] | Fair Value of Forward Option [Member] | Fair Value, Recurring [Member]
Total Liabilities
Level 1 [Member] | Trading Securities [Member] | Fair Value, Recurring [Member]
Total assets
Level 2 [Member] | Fair Value, Recurring [Member]
Total assets	521,615
Total Liabilities
Level 2 [Member] | Short-term Loan Measured at Fair Value | Fair Value, Recurring [Member]
Total assets
Level 2 [Member] | Fair Value of Convertible Component in Convertible Notes [Member] | Fair Value, Recurring [Member]
Total Liabilities
Level 2 [Member] | Fair Value of Forward Option [Member] | Fair Value, Recurring [Member]
Total Liabilities
Level 2 [Member] | Trading Securities [Member] | Fair Value, Recurring [Member]
Total assets	521,615
Level 3 [Member] | Fair Value, Recurring [Member]
Total assets	165,185
Total Liabilities	452,869
Level 3 [Member] | Short-term Loan Measured at Fair Value | Fair Value, Recurring [Member]
Total assets	165,185
Level 3 [Member] | Fair Value of Convertible Component in Convertible Notes [Member] | Fair Value, Recurring [Member]
Total Liabilities	381,147
Level 3 [Member] | Fair Value of Forward Option [Member] | Fair Value, Recurring [Member]
Total Liabilities	71,722
Level 3 [Member] | Trading Securities [Member] | Fair Value, Recurring [Member]
Total assets

Summary of Significant Accoun_6

Summary of Significant Accounting Policies and Basis of Presentation - Schedule of Changes in Fair Value of Liabilities (Details) - Level 3 [Member]	12 Months Ended
	Dec. 31, 2020USD ($)
Outstanding at January 1, 2020
Fair value of issued level 3 assets	145,000
Changes in fair value	20,185
Outstanding at December 31, 2020	165,185
Outstanding at January 1, 2020
Fair value of issued level 3 liability	350,608
Changes in fair value	102,261
Outstanding at December 31, 2020	$ 452,869

Investment Valued Under the M_2

Investment Valued Under the Measurement Alternative (Details Narrative) - USD ($)	Jun. 22, 2020	Nov. 22, 2020
Equity investment percentage		50.00%
Nanomedic Technologies Ltd [Member] | Share Purchase Agreement [Member] | A-1 Preferred Shares [Member]
Payments for purchase of preferred stock	$ 450,000
Equity investment percentage	3.30%
Proceeds from issuance of preferred stock	$ 2,200,000

Sale of Novomic (Details Narrat

Sale of Novomic (Details Narrative)	Jan. 06, 2020
Traistman Radziejewski Fundacja Ltd. [Member]
Percentage of shares sold	90.00%

Sale of Novomic - Summary of De

Sale of Novomic - Summary of Deconsolidation of a Subsidiary (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Cash and cash equivalents	$ 13,810
Working capital (excluding cash and cash equivalents), net (deficit)	(217,111)
Long term assets	155,988
Long term liabilities	(5,017)
Total value of a subsidiary	(52,330)
Amounts received
GAIN FROM DECONSOLIDATION OF A SUBSIDIARY	$ 52,330

Convertible Notes (Details Narr

Convertible Notes (Details Narrative) - USD ($)	Apr. 12, 2021	Jun. 12, 2020	Apr. 02, 2020	Dec. 31, 2020	Dec. 31, 2019	Apr. 19, 2020
Warrants issued in connection with convertible notes (Note 5)				$ 301,665
Common Stock [Member]
Warrants issued in connection with convertible notes (Note 5)
CL Agreement [Member]
Notes payable		$ 1,000,000				$ 170,000
Description on agreement terms		The CL Agreement was amended (hereafter "Amendment") to provide that for each draw down made by the Company under the CL Agreement, the Buyer shall be entitled to receive two types of warrants: A warrants and B warrants, with the A warrants exercisable at any time between 6 and 12 months after issuance for an exercise price per share equal to 1.25 times the average of the closing prices of the 3 trading days preceding the draw down, and the B warrants exercisable at any time between 6 and 24 months after issuance for an exercise price per share equal to 1.5 times the average of the closing prices of the 5 trading days preceding the draw down, and that the number of each of the A warrants and the B warrants issued will be equal to the draw down amount divided by the average of the closing prices of the 3 trading days preceding the draw down, and that these amended terms will apply in respect of all draw downs, including drawdowns made prior to the date of the amendment.
Convertible notes		$ 580,925
CL Agreement [Member] | Warrants A [Member]
Issued a warrant to purchase common stock		5,589,172
CL Agreement [Member] | Warrants B [Member]
Issued a warrant to purchase common stock		5,589,172
CL Agreement [Member] | Common Stock [Member]
Issued a warrant to purchase common stock		11,178,344
CL Agreement [Member] | Forecast [Member] | Maximum [Member]
Repayment of notes payable	$ 5,000,000
Buyer [Member] | CL Agreement [Member] | Notes [Member]
Principal amount			$ 1,800,000
Debt instrument interest percentage			6.00%
Common stock conversion price			$ 0.85
Discount percentage			15.00%
Debt instrument maturity description			Each Note will mature 18 months following the payment date.

Convertible Notes - Schedule of

Convertible Notes - Schedule of Fair Value of Convertible Feature using Valuation Assumptions (Details) - Black-Scholes Option-Pricing Model [Member] - USD ($)		Jun. 12, 2020	Dec. 31, 2020
Expected volatility (%)		64.71%	164.43%
Risk-free interest rate (%)		0.18%	0.10%
Expected dividend yield		0.00%	0.00%
Contractual term (years)		1 year 6 months	11 months 12 days
Conversion price	[1]
Underlying share price (U.S. dollars)		$ 0.21	$ 0.045
Convertible notes amount		$ 1,275,204	$ 1,275,204
Fair value of the conversion feature (U.S. dollars)		$ 285,028	$ 381,147
[1]	the conversion price is 85% of the share price, during the period of 5 days preceding the conversion date.

Convertible Notes - Schedule _2

Convertible Notes - Schedule of Fair Value of Convertible Feature using Valuation Assumptions (Details) (Parenthetical)	Dec. 31, 2020	Jun. 12, 2020
Black-Scholes Option-Pricing Model [Member]
Conversion price percentage	85.00%	85.00%

Convertible Notes - Summary of

Convertible Notes - Summary of Warrants (Details)	Dec. 31, 2020$ / shares
Measurement Input, Share Price [Member] | Warrants A [Member]
Common stock price	$ 0.21
Measurement Input, Share Price [Member] | Warrants B [Member]
Common stock price	$ 0.21
Expected Volatility [Member] | Warrants A [Member]
Fair value of warrant liability, measurement input, percentage	65.31
Expected Volatility [Member] | Warrants B [Member]
Fair value of warrant liability, measurement input, percentage	68.73
Expected Term [Member] | Warrants A [Member]
Fair value assumption, warrant contractual term (years)	1 year
Expected Term [Member] | Warrants B [Member]
Fair value assumption, warrant contractual term (years)	2 years
Risk Free Rate [Member] | Warrants A [Member]
Fair value of warrant liability, measurement input, percentage	0.17
Risk Free Rate [Member] | Warrants B [Member]
Fair value of warrant liability, measurement input, percentage	0.19
Expected Dividend Yield [Member] | Warrants A [Member]
Fair value of warrant liability, measurement input, percentage	0
Expected Dividend Yield [Member] | Warrants B [Member]
Fair value of warrant liability, measurement input, percentage	0

Shareholders' Equity (Details N

Shareholders' Equity (Details Narrative) - USD ($)

Nov. 22, 2020

Nov. 12, 2020

Nov. 11, 2020

Mar. 05, 2020

Feb. 23, 2020

Jan. 29, 2020

Mar. 31, 2020

Feb. 29, 2020

Dec. 31, 2020

Dec. 31, 2019

Nov. 08, 2020

May 14, 2020

Common stock, par value

$ 0.0001

$ 0.0001

Value of common stock shares issued

$ 177,000

Fair value of service

$ 9,158,064

Reverse stock split

On November 22, 2020, certain of the Company's stockholders representing more than 50% of the Company's outstanding share capital (the "Majority Consenting Stockholders") approved an amendment to the Company's Certificate of Incorporation (the "Reverse Stock Split Certificate of Amendment") in order to effect a reverse stock split of the Company's common stock pursuant to a range of between 40-to-1 and 100-to-1 (the "Reverse Stock Split").

On October 8, 2020, the Board approved a reverse stock split of the Company's authorized, issued and outstanding shares of Common Stock, at a ratio between 1-for-40 to 1-for-100, subject to the approval of the Company's stockholders (the "Reverse Stock Split"). The final ratio of the Reverse Stock Split will be determined by the Board at a later date.

Preferred stock, shares authorized

(37,586,206)

(37,586,206)

Investors [Member]

Common stock, par value

$ 0.0001

$ 0.0001

Legal Advisor [Member]

Fair value of shares issued

13,222,082

15,000,000

Fair value of service

$ 4,785,000

Stock-based compensation

3,751,000

Chief Financial Officer [Member]

Fair value of shares issued

1,411,104

Fair value of service

155,000

AR Citrine Agreement [Member] | Maximum [Member]

Number of common stock shares issued

893,699,276

Certificate of Incorporation [Member]

Increase in shares authorized

1,000,000,000

Agreement [Member] | Legal Advisor [Member]

Fair value of service

4,218,000

Stock-based compensation

$ 2,109,000

Common Stock [Member]

Shares issued upon conversion

10,344,828

Number of common stock shares issued

445,702,721

864,997,122

Value of common stock shares issued

$ 86,500

Fair value of shares issued

29,633,186

Fair value of service

$ 2,963

Common Stock [Member] | Investors [Member]

Number of common stock shares issued

432,996,555

432,996,555

Value of common stock shares issued

$ 45,000

$ 45,000

Undesignated Preferred Stock [Member]

Preferred stock, shares authorized

(50,000,000)

Redeemable Convertible Series A Preferred Stock [Member]

Number of redeemable preferred stock issued, shares converted

10,344,828

Stock Options (Details Narrativ

Stock Options (Details Narrative)	1 Months Ended
	Mar. 31, 2017$ / sharesshares
Share-based Payment Arrangement [Abstract]
Granted to non-employees options to purchase | shares	521,065
Common stock for exercise price per share | $ / shares	$ 0.0001
Date of the grant	5 years

Stock Options - Schedule of Sto

Stock Options - Schedule of Stock Option Activity (Details) - $ / shares	1 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2020
Number of Options, Granted	521,065
Weighted Average Exercise Price, Granted	$ 0.0001
Employees and Directors [Member]
Number of Options outstanding, beginning balance		521,065
Number of Options, Granted
Number of Options, Exercised
Number of Options, Forfeited or expired		(474,303)
Number of Options, outstanding, ending balance		46,762
Options exercisable, ending balance		46,762
Weighted Average Exercise Price outstanding, beginning balance		$ 0.0011
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited or expired		0.0011
Weighted Average Exercise Price, ending balance		0.0011
Weighted Average Exercise Price, Options exercisable, ending balance		$ 0.0011

Agreements With Intelicanna L_3

Agreements With Intelicanna Ltd (Details Narrative)	Sep. 17, 2020USD ($)shares	Jul. 09, 2020USD ($)	Jul. 09, 2020ILS (₪)	Jun. 25, 2020ILS (₪)	May 31, 2020	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Value of common stock shares issued						$ 177,000
Fair value of a liability in connection with stock exchange agreement						71,722
Common Stock [Member]
Value of common stock shares issued						$ 86,500
Intelicanna Ltd. [Member]
Number of ordinary shares exchanged | shares	2,143,470
Fair value of change in traded securities	$ 50,000
Intelicanna Ltd. [Member] | Common Stock [Member]
Shares issued upon exchange	619,589
Intelicanna Ltd. [Member] | Share Exchange Agreement [Member]
Description on agreement terms					The Share Exchange Agreement provides that (i) the number of shares each party issues to the other will be calculated by dividing $500 thousand by the volume weighted average price (VWAP) of the issuing party's shares in the three trading days preceding the signing of the agreement, (ii) the issuance by Intelicanna will take place upon, and subject to, receipt of approval from the Tel Aviv Stock Exchange, and the issuance by the Company will follow immediately thereafter, and (iii) the parties may not sell the shares within the first six months after issuance, and thereafter the parties may sell the shares issued to them if the shares become registered through a prospectus approved by the relevant securities authority, or under an exemption provided by applicable securities law, subject to a limit on the number of shares either party may sell per day. The Agreement for future Issuance of Shares provides that a fall in a share price of a party, not exceeding 20%, measured six months after issuance of shares by both parties pursuant the Share Exchange Agreement, will be offset by the issuance of additional shares to the other party to bring up to $500 thousand the total value of the shares issued to the other party.
Intelicanna Ltd. [Member] | Services Agreement [Member]
Payments for loan		$ 145,000
Intelicanna Ltd. [Member] | Services Agreement [Member] | NIS [Member]
Payments for loan | ₪			₪ 500,000
Citrine Global Israel Ltd. [Member] | Services Agreement [Member]
Description on agreement terms				Intelicanna to raise the first NIS 1 million towards the up to NIS 15 million mentioned in the Services Agreement, the Company and the Israeli Subsidiary entered into an agreement to grant Intelicanna NIS 1 million in cash (approximately USD 290 thousand) in direct financing for working capital purposes. The financing will bear 6% annual interest and Intelicanna will make additional payments equalling 6% of its gross revenues between the date the financing is received and the date Intelicanna's aggregate gross revenues thereafter equal NIS 2 million. If the total of the 6% interest plus the additional payments would result in a return of less than 12% in the year to the Company, the interest will be increased to bring the total return to 12%. Every three months Intelicanna must pay the interest, and after 12 months, it must repay the capital, plus the total of the additional payments due, plus any outstanding interest, and it must pay interest of 2% per month on any late payments, provided however that until the foregoing obligations are paid in full Intelicanna must pay 50% of its gross revenues to the Company upon receipt. If Intelicanna does not pay all amounts due within 18 months, it shall, at the Company's option, issue to the Company a number of its shares equal to NIS 1.5 million divided by the lower of (i) VWAP of the three trading days prior to the lapse of the 18 months, and (ii) VWAP of the three trading days prior to the signing of the financing agreement. The financing must be paid by the Company to Intelicanna within 30 days of signing the financing agreement, subject to completion of due diligence to the Company's satisfaction and to Intelicanna receiving a commercial growing license.
Percentage of gross revenue				50.00%
Debt instrument interest percentage				6.00%
Citrine Global Israel Ltd. [Member] | Services Agreement [Member] | NIS [Member]
Description on agreement terms				Israeli Subsidiary entered into a services agreement with Intelicanna to provide business development and consulting services to Intelicanna, including assistance with raising financing (the "Services Agreement") (references in this paragraph to the Company include the Israeli Subsidiary). The terms of the Services Agreement include: (1) the Company will, for a period of 18 months, assist Intelicanna to raise up to NIS 15 million for Intelicanna's working capital purposes, whether through issuance of convertible securities or any other means; all sums raised must be approved in advance by the Company, and in accordance with a business plan presented to the Company from time to time; the Company will have no obligation under the Services Agreement to invest in Intelicanna, and no liability if its efforts to source financing for Intelicanna are unsuccessful; (2) in the event Intelicanna raises funds through assistance from the Company, the Company will be entitled to (i) cash consideration equal to 5% of any amount raised, whether directly from the Company, or from any of its affiliates or any unrelated third party, and (ii) options to acquire a number of shares of Intelicanna equal to 5% of the amount raised divided by the Exercise Price; the "Exercise Price" will be the price per share at which the amount was raised, or if it was not raised through issuance of shares, the price per share at which Intelicanna last raised funds through issuance of shares; and (3) for one or more periods of at least 90 days, each time at Intelicanna's request which the Company may accept or decline at its discretion, the Company will provide business development and strategy-building services, including: consulting on strategy and business plan; assistance defining financing needs; helping identify ways to develop potential sources of finance; and ongoing consulting support to Intelicanna's management team and board. Intelicanna will pay the Company a fee of NIS 2,500 per day for such services.
Value of common stock shares issued | ₪				₪ 15,000,000
Fee for service rendered | ₪				2,500
Aggregate gross revenues | ₪				₪ 2,000,000

Agreements With Intelicanna L_4

Agreements With Intelicanna Ltd - Schedule of Fair Value of Shares Exchange Agreement (Details)	12 Months Ended
	Dec. 31, 2020USD ($)$ / shares
Derivative Related to Intelicanna's Shares [Member]
Fair value of the derivative | $	$ 27,975
Derivative Related to Citrine Global's Shares [Member]
Fair value of the derivative | $	$ (99,697)
Measurement Input, Share Price [Member] | Derivative Related to Intelicanna's Shares [Member]
Common stock price, shares | $ / shares	$ 0.83
Measurement Input, Share Price [Member] | Derivative Related to Citrine Global's Shares [Member]
Common stock price, shares | $ / shares	$ 0.046
Measurement Input, Price Volatility [Member] | Derivative Related to Intelicanna's Shares [Member]
Fair value of shares, measurement input, percentage	57.61
Measurement Input, Price Volatility [Member] | Derivative Related to Citrine Global's Shares [Member]
Fair value of shares, measurement input, percentage	125.19
Expected Term [Member] | Derivative Related to Intelicanna's Shares [Member]
Fair value assumption, shares contractual term (years)	3 years 1 month
Expected Term [Member] | Derivative Related to Citrine Global's Shares [Member]
Fair value assumption, shares contractual term (years)	3 years 1 month
Conversion Price (U.S. Dollars) [Member] | Derivative Related to Intelicanna's Shares [Member]
Fair value of shares, measurement input, percentage	0.64
Risk Free Rate [Member] | Derivative Related to Intelicanna's Shares [Member]
Fair value of shares, measurement input, percentage	0.09
Risk Free Rate [Member] | Derivative Related to Citrine Global's Shares [Member]
Fair value of shares, measurement input, percentage	0.09
Expected Dividend Yield [Member] | Derivative Related to Intelicanna's Shares [Member]
Fair value of shares, measurement input, percentage	0
Expected Dividend Yield [Member] | Derivative Related to Citrine Global's Shares [Member]
Fair value of shares, measurement input, percentage	0
Conversion Price (U.S. dollars) [Member] | Derivative Related to Citrine Global's Shares [Member]
Fair value of shares, measurement input, percentage	0.2

Related Parties (Details Narrat

Related Parties (Details Narrative)

Aug. 04, 2020

Nov. 17, 2019USD ($)$ / sharesshares

Aug. 20, 2019USD ($)$ / sharesshares

Apr. 28, 2019USD ($)$ / sharesshares

Dec. 31, 2017USD ($)

Feb. 22, 2017USD ($)

Feb. 22, 2017ILS (₪)

Jul. 31, 2016USD ($)

Nov. 11, 2014USD ($)

Dec. 31, 2020USD ($)

Dec. 31, 2019USD ($)

May 31, 2020USD ($)

Feb. 29, 2020USD ($)

Oct. 23, 2019USD ($)

Oct. 23, 2019ILS (₪)

Jul. 31, 2016ILS (₪)

Dec. 31, 2015USD ($)

Dec. 31, 2015ILS (₪)

May 31, 2015ILS (₪)

Nov. 11, 2014ILS (₪)

Related Party Transaction [Line Items]

Proceeds from issuance of common stock

$ 177,000

$ 457,455

Ora Meir Soffer [Member]

Related Party Transaction [Line Items]

Due from related parties

$ 20,000

Compensation earned

$ 210,200

Equity method investment. description

An amount of $210,200 represent compensation earned by Ora Elharar Soffer during the year ended December 31, 2020 but that was deferred until the Company consummated an investment of at least $1.8 million in the Company's securities.

Ilanit Halperin [Member]

Related Party Transaction [Line Items]

Due from related parties

3,500

Compensation earned

$ 66,164

Equity method investment. description

An amount of $66,164 represent compensation earned by Ilanit Halperin during the year ended December 31, 2020 but was deferred until the Company consummated an investment of at least $1.8 million in the Company's securities.

Ilanit Halperin Ilan BenIshay [Member]

Related Party Transaction [Line Items]

Compensation earned

$ 34,109

Equity method investment. description

An amount of $34,109 represent compensation earned by Ilan Ben-Ishay during the year ended December 31, 2020 but that was deferred until the Company consummated an investment of at least $1.8 million in the Company's securities.

Ilan Ben-Ishay [Member]

Related Party Transaction [Line Items]

Due from related parties

$ 3,500

Ilanit Halperin and Ilan Ben-Ishay [Member]

Related Party Transaction [Line Items]

Due from related parties

$ 7,000

Israeli Subsdiary [Member]

Related Party Transaction [Line Items]

Description on agreement terms

On August 4, 2020, the Board of directors of the Company approved for the Company and/or the Israeli Subsidiary (references in this paragraph to the Company include the Israeli Subsidiary) to proceed with preparations for investing iBOT. iBOT has a manufacturing facility for a wide range of botanical formulations, and part of its strategy is to combine this with hemp and CBD. The board gave its approval, subject to agreement of definitive terms and receipt of all necessary corporate and other approvals, for a proposed transaction in which (1) the Company would have an option to make one or more investments during a period of 12 months in an aggregate amount of up to $1 million (one million U.S. dollars); (2) the investments may be through loans, direct equity purchases, or other means, and would be based on milestones; and (3) iBOT would grant the Company a 25% discount in its next fundraising. In addition, the Board approved for the Company to proceed with preparations for entering a services agreement with iBOT pursuant to which the Company would provide consulting and other services to iBOT. iBOT is controlled by an affiliate of the Company. As of the date of these financial statements, such agreements have not yet been signed and the Company is still in the process of examining the cooperation and investment in iBOT.

Consulting Agreement [Member] | Mr. Yossef De-Levy [Member]

Related Party Transaction [Line Items]

Due from related parties

Termination date

Mar. 16, 2020

Consulting Agreement [Member] | Mr. Yossef De-Levy [Member] | NIS [Member]

Related Party Transaction [Line Items]

Due from related parties | ₪

₪ 10,000

₪ 5,000

Consulting Agreement [Member] | Zvi Yemini [Member]

Related Party Transaction [Line Items]

Due from related parties

$ 6,200

Consulting Agreement [Member] | Zvi Yemini [Member] | NIS [Member]

Related Party Transaction [Line Items]

Due from related parties | ₪

₪ 24,000

Consulting Agreement [Member] | Oren Traistman [Member]

Related Party Transaction [Line Items]

Due from related parties

$ 2,900

Termination date

Mar. 16, 2020

Consulting Agreement [Member] | Oren Traistman [Member] | NIS [Member]

Related Party Transaction [Line Items]

Due from related parties | ₪

₪ 10,000

Consulting Agreement [Member] | Ran Tuttnauer [Member]

Related Party Transaction [Line Items]

Due from related parties

$ 2,000

Termination date

Apr. 30, 2019

Consulting Agreement [Member] | Idan Traitsman [Member]

Related Party Transaction [Line Items]

Due from related parties

$ 2,800

Consulting Agreement [Member] | Idan Traitsman [Member] | NIS [Member]

Related Party Transaction [Line Items]

Due from related parties | ₪

₪ 10,000

Original Service Agreement [Member] | Zvi Yemini [Member]

Related Party Transaction [Line Items]

Termination date

Nov. 14, 2019

Nov. 14, 2019

Increase in monthly payments, amount

$ 13,000

Original Service Agreement [Member] | Zvi Yemini [Member] | NIS [Member]

Related Party Transaction [Line Items]

Increase in monthly payments, amount | ₪

₪ 45,000

Securities Purchase Agreement [Member] | Y.M.Y. Industry Ltd [Member]

Related Party Transaction [Line Items]

Option to purchase shares of common stock | shares

1,229,508

Shares issued, price per share | $ / shares

$ 0.183

Proceeds from issuance of common stock

$ 225,000

Securities Purchase Agreement [Member] | Traistman Radziejewski Fundacja Ltd. [Member]

Related Party Transaction [Line Items]

Option to purchase shares of common stock | shares

1,229,508

Shares issued, price per share | $ / shares

$ 0.183

Proceeds from issuance of common stock

$ 225,000

Securities Purchase Agreement [Member] | Microdel Ltd. [Member]

Related Party Transaction [Line Items]

Option to purchase shares of common stock | shares

1,229,508

Shares issued, price per share | $ / shares

$ 0.183

Proceeds from issuance of common stock

$ 225,000

Securities Purchase Agreement [Member] | Y.M.Y and TRF [Member] | Series A convertible Preferred Stock [Member]

Related Party Transaction [Line Items]

Option to purchase shares of common stock | shares

2,068,966

8,275,862

Shares issued, price per share | $ / shares

$ 0.029

$ 0.029

Proceeds from issuance of common stock

$ 60,000

$ 240,000

Securities Purchase Agreement [Member] | Option for Period of Twelve Months [Member] | Y.M.Y. Industry Ltd [Member]

Related Party Transaction [Line Items]

Option to purchase shares of common stock | shares

375,001

Shares issued, price per share | $ / shares

$ 0.60

Proceeds from issuance of common stock

$ 225,000

Securities Purchase Agreement [Member] | Option for Period of Twelve Months [Member] | Traistman Radziejewski Fundacja Ltd. [Member]

Related Party Transaction [Line Items]

Option to purchase shares of common stock | shares

375,001

Shares issued, price per share | $ / shares

$ 0.60

Proceeds from issuance of common stock

$ 225,000

Securities Purchase Agreement [Member] | Option for Period of Twelve Months [Member] | Microdel Ltd. [Member]

Related Party Transaction [Line Items]

Option to purchase shares of common stock | shares

375,001

Shares issued, price per share | $ / shares

$ 0.60

Proceeds from issuance of common stock

$ 225,000

Securities Purchase Agreement [Member] | Option for Period of Twelve Months [Member] | Y.M.Y and TRF [Member] | Series A convertible Preferred Stock [Member]

Related Party Transaction [Line Items]

Option to purchase shares of common stock | shares

400,000

Shares issued, price per share | $ / shares

$ 0.60

Proceeds from issuance of common stock

$ 240,000

Securities Purchase Agreement [Member] | 2020 Purchase [Member] | Y.M.Y and TRF [Member] | Investors [Member]

Related Party Transaction [Line Items]

Option to purchase shares of common stock | shares

45,000

Shares issued, price per share | $ / shares

$ 0.60

Proceeds from issuance of common stock

$ 27,000

Securities Purchase Agreement [Member] | 2020 Purchase [Member] | Y.M.Y and TRF [Member] | Series A convertible Preferred Stock [Member]

Related Party Transaction [Line Items]

Option to purchase shares of common stock | shares

931,034

Shares issued, price per share | $ / shares

$ 0.029

Proceeds from issuance of common stock

$ 27,000

Securities Purchase Agreement [Member] | 2019 Purchase [Member] | Y.M.Y and TRF [Member] | Investors [Member]

Related Party Transaction [Line Items]

Option to purchase shares of common stock | shares

100,000

Shares issued, price per share | $ / shares

$ 0.60

Proceeds from issuance of common stock

$ 60,000

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	Dec. 22, 2017	Dec. 31, 2020	Dec. 31, 2019
Net operating carry forward		$ 1,795,036
Subsidiaries [Member]
Net operating carry forward		$ 53,019
Novomics [Member]
Net operating carry forward			$ 7,725,000
January 1, 2018 [Member]
Corporate tax rate	21.00%
Israel Tax [Member]
Corporate tax rate		23.00%

Income Tax - Schedule of Reconc

Income Tax - Schedule of Reconciliation of Effective Tax Rate (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Pretax loss	$ (8,639,159)	$ (1,874,135)
Federal tax rate	21.00%	21.00%
Income tax computed at the ordinary tax rate	$ 1,814,223	$ 393,568
Non-deductible expenses	874	6,831
Stock-based compensation	1,558,520	2,618
Fair value adjustments	41,468
Tax in respect of differences in corporate tax rates	(1,060)	(32,463)
Losses and timing differences in respect of which no deferred taxes were generated	214,421	416,582
Total Income tax

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Research and Development credit carry forwards		$ 41,417
Provision for slow moving inventory		40,522
Non capital loss carry forwards	362,385	1,959,070
Valuation allowance	(362,385)	(2,041,009)
Total deferred tax assets

Loss Per Share - Schedule of Ba

Loss Per Share - Schedule of Basic and Diluted Loss Per Ordinary Share (Details) - shares		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019
Earnings Per Share [Abstract]
Weighted average number of shares of Common Stock outstanding attributable to ordinary shareholders		476,622,892	37,473,278
Total weighted average number of shares of Common Stock related to outstanding options, excluded from the calculations of diluted loss per share	[1]	46,762	46,762
[1]	The effect of the inclusion of option and convertible loans in 2020 and 2019 is anti-dilutive.

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($)	Apr. 12, 2021	Mar. 31, 2021
Agreement [Member]
Debt instrument interest rate	9.00%
Agreement [Member] | A Warrants and B Warrants [Member]
Investment	$ 5,000,000
Exercise price per share	$ 0.10
Intelicanna [Member]
Interest receivable		$ 12